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Introduction 
The genome sequencing projects reveal that integral membrane proteins represent up to 
one third of the predicted proteins of all organisms examined so far. Furthermore, membrane 
proteins are targets of the large majority of the drugs that are currently in use. About 80% of 
all cellular responses are thought to occur through the proteins linked to the cell membrane. 
An ultimate understanding of their function depends on detailed structural data for each class 
of membrane proteins, such as transporters, receptors, channels and pumps. The structural 
information could also greatly improve the efficiency of drug discovery [1–4]. To date, the 
3D structures of only a tiny fraction of membrane proteins (around 218) are known in atomic 
detail, though structures of around 50000 soluble proteins have already been solved [5,6]. 
Difficulties to determine 3D structures of integral membrane proteins are most notably 
related to their hydrophobic/hydrophilic nature and inhomogeneity due to post-translational 
modifications. They are expressed at rather low levels and usually constitute less than 30% of 
a total cellular protein [7]. This requires developing an efficient overexpression system to 
produce sufficient amounts of protein for crystallization experiments. In general, the term 
“overexpression” is used to describe the production of proteins at a level that exceeds the 
endogenous one, e.g., 10-100 mg of protein per liter of culture. In spite of recent advances in 
nano volume crystallization technics and methods, still, for systematic 3D crystallization 
experiments, milligrams of highly pure protein are required. However, only a few membrane 
proteins are abundant enough in natural sources. An expression level of 0.2 mg per 1 liter of 
culture will already be limiting. Indeed, one should take into account that the overall yield of 
the purification procedure is generally very low. 
The second limitation for the study of membrane proteins is extreme hydrophobicity due 
to hydrophobic nature of their membrane embedded part. This makes them refractory to direct 
manipulation in aqueous solutions and necessitates the use of detergents for their functional 
solubilization from the membrane and maintenance of their solubility throughout the 
purification process. 
Many eukaryotic membrane proteins are post-translationally modified. Since 
modifications are usually incomplete, this is a source of inhomogeneity that interferes with 
successful protein crystallization. Overexpression systems allow genetic engineering of the 
target protein in order to prevent the modification that usually yield more homogeneous 
protein and preserve protein function. 
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The choice of the expression system is critical to obtaining a functional protein. An 
overexpression system can be either homologous or heterologous. Both systems have their 
specific advantages and limitations, like efficient overexpression of a given target membrane 
protein, the genetic characterization, the amenability to manipulation and the cost. The 
organisms commonly used for protein overexpression are bacteria (Escherichia coli), yeasts 
(Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris), baculovirus/insect 
cells, and mammalian cells. 
E.coli is a convenient host for heterologous protein expression. Its advantages include 
well-established protocols, fast growth, high levels of heterologous gene expression and 
scalability of experiments and low cost. It is also important to mention that 80% of all protein 
structures deposited in the protein data bank were obtained with the proteins overexpressed in 
E.coli [8]. However, heterologous gene expression in E.coli can lead to the production of 
misfolded, aggregated, and/or nonfunctional target proteins. This is often due to the absence 
of cofactors or lack of post-translational modifications required for function, stability and 
folding. 
Taken together these features make the development of methods for the study of 
membrane proteins lag far behind those of soluble proteins. Finally, one has to point out that 
large amounts of pure and homogeneous protein are absolute prerequisites to begin with 
crystallization experiments.  
Connexins belong to a very important class of membrane proteins. Till now, 21 human, 
20 mouse, and 20 rat connexin genes have been identified. In living organisms connexins are 
the principal protein component of gap junctions – specialized cell-cell junctions that directly 
link the cytoplasm of adjacent cells. They mediate the direct transfer of low-molecular-weight 
(<1.2 kDa) metabolites and ions, including second messengers. It has been hypothesized that 
gap junctional intercellular communication plays a crucial role in the maintenance of 
homeostasis, morphogenesis, cell differentiation, and growth control in multicellular 
organisms. Recently it was shown that connexin 43 plays an important role in transformation 
of somatic cells to pluripotent ones. Discoveries of human genetic disorders due to mutations 
in gap junction protein genes and experimental data on connexin knockout mice provide the 
direct evidence that gap junctional intercellular communication is essential for tissue 
functions and organs development, and that its dysfunction causes diseases. At least nine 
human maladies are currently associated with mutations in genes encoding connexins. Also 
there are strong evidences that connexins function as malignant tumor suppressors [9]. 
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Taking into account their relevance and impact connexin studies have been started long 
time ago and connexins are still actively explored. At present a lot of information about 
connexin physiology, permeability and disease-causing mutations was collected. But still 
atomic resolution structure of gap junction (formed by human connexin 26) is the only 
available [10]. This is mostly explained by high complexity of overexpression and 
purification of connexins in sufficient for crystallization amounts in mammalian or insect 
cells, which are commonly used for functional expression of mammalian proteins. The second 
problem is that connexins are subjected to post-translational modifications, which need to be 
removed to proceed with crystallization. And each additional purification step is crucial for 
final protein yield. On the other hand expression of recombinant proteins in E.coli eliminates 
most post-translational modifications and therefore would have an important advantage. 
Furthermore, it was previously shown that overexpression of connexins 26 and 43 in E.coli is 
possible and functional protein can be purified (able to form hexameric hemichannels and to 
bind ligands) [11–13]. 
Human connexin 32 is the major component of the peripheral myelin and is expressed in 
hepatocytes, secretory acinar cells, and Schwann cells as well. Among other members of 
connexin family it is one of the best studied. A lot of data concerning its conductance and 
permeability properties are available. Furthermore, connexin 32 was previously successfully 
produced and purified from mammalian cells [14], in vitro (using mammalian cells extract) 
[15], and from baculovirus/insect cells [16]. That is why there is a possibility to compare 
functional properties of this connexin overexpressed in different systems. However, previous 
attempts to express and purify full-length connexin 32 from E.coli were not successful [17]. 
In our work, we show that this is indeed possible. We developed the protocol of expression 
and purification of functional protein, able to form hemichannels. It is important to stress that 
there is no experimental atomic resolution structure of connexin 32 that can help to 
understand the molecular mechanism of its function. Two structural models of human 
connexin 32 were proposed [18,19]. In both cases they were created on basis of cryo-electron 
microscopy maps obtained for connexin 43 [20]. However, a high-resolution X-Ray structure 
of connexin 32 is to be obtained. We recently expressed the connexin in E.coli, solubilized 
and purified the protein and performed its first functional tests. The amount of protein is 
sufficient to start crystallization trials. 
To summarize, in this work we overexpressed connexin 32 using membrane-targeting 
expression tag. Membrane-integrating protein MstX from Bacillus subtilis was attached to N-
terminus of Cx32 and helped to increase tremendously expression yield. Since addition of N-
 9 
terminal extensions suppresses connexins functions all excessive amino acids must be 
removed. We demonstrated that MstX is resistant to various cleavage conditions including 
different proteases usage and variations of linker in between. Also we expressed Cx32 
without any expression tag in vitro using E.coli S30 extract and refolded purified connexins 
into hemichannels. Then, since expression yield was still not high enough (around 0.2 mg of 
Cx32 per 1 ml of in vitro reaction mixture), we performed a broad screening of cell free 
reaction conditions and examined influence of short peptides addition on N-terminus. Next, 
we managed to express and purify connexin 32 from E.coli using certain gene sequence 
optimization. A refolding procedure was developed and Cx32 functionality was confirmed by 
assembling it into hemichannels. Further this protein was used for crystallization experiments.  
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Main results 
Human connexin 32 gene was optimized for E.coli expression. hCx32 was produced in E.coli 
without any expression enhancers. The same purification and refolding protocol was used as 
for in vitro expressed connexin. Electron microscopy and dynamic light scattering confirmed 
proper oligomerization state of resulting Cx32 refolded in amphipol. This protein was used 
for in meso crystallization. 
 
Human connexin 32 was expressed in vitro using E.coli S30 extract. A broad screening of cell 
free reaction conditions was carried out in order to increase protein yield. For the same reason 
influence of short peptides fused with N-terminus of Cx32 was examined. Finally, a suitable 
purification protocol was derived with the yield of Cx32 of 0.2 mg per 1 ml of in vitro 
reaction mixture. Protein was purified to homogeneity in NLS and SDS. The procedure 
resulting in assembling of Cx32 into connexons was suggested. 
 
We also performed a number of other studies before we found an efficient approach to 
expressing hCx32. Among them we would like to mention that: 
 
Human connexin 32 was successfully overexpressed using membrane-targeting expression 
tag in E.coli. Membrane-integrating protein MstX from Bacillus subtilis was attached to N-
terminus of Cx32 and helped to increase tremendously expression yield. Since addition of N-
terminal extensions suppresses connexins functions all excessive amino acids must be 
removed. We demonstrated that MstX-Cx32 was resistant to various cleavage conditions 
including different proteases usage and variations of linker in between.
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1. Literature overview 
1.1. The family of connexin genes 
1.1.1. Introduction and nomenclature 
Connexins constitute a large family of trans-membrane proteins that allow intercellular 
communication by forming gap junction channels [21–24]. The first members of this family 
were isolated by screening of complementary DNA (cDNA) libraries using antibodies 
directed against purified gap junctions to detect expressed fusion proteins [21] or by 
hybridization with oligonucleotides corresponding to amino acid sequences derived from the 
purified proteins [22]. Subsequently, additional members were identified from cDNA and 
genomic DNA based on their sequence similarities to those of known connexins [24–26].  
Though connexin genes have been found only in deuterostomes other intercellular 
channels and gap junction structures are identified in many lower multicellular organisms. 
Proteins named innexins are forming gap junctions in most invertebrates. They show 
membrane topology similar to that of the connexins, but their gene sequences differ from the 
connexins a lot [27–29].  Also there are three genes, called pannexins, in genomes of higher 
vertebrates that exhibit high level of predicted amino acid sequences identity to the innexins 
[30]. Although pannexins can form channels connecting the cytoplasm and extracellular 
space, like connexin hemichannels, it was not proven that they form intercellular channels in 
living nature except in certain overexpression systems [31–33].  
Till now 21 human genes and 20 mouse genes for connexins have been identified [34]. 
Each connexin is expressed in specific tissues or cell types and many cell types express more 
than one connexin (Table 1.1). Some connexins are expressed in cells of many types, but 
others are expressed in very limited organs and cells. Even in the same tissue, the expression 
pattern of each connexin shows cell-type specificity and developmental changes, suggesting 
the presence of distinct but tight control mechanisms for regulation of connexin gene 
expression. 
All members of the connexin protein family are denoted using a standard, operational 
nomenclature that utilizes the word connexin  (abbreviated Cx) followed by a suffix 
indicating the predicted molecular mass of the polypeptide in kilodaltons [35].  There also 
exists another nomenclature for identification of connexins. This system was initially 
developed when vertebrate connexin genes were separated into subgroups, α, β and γ, on the 
basis of overall sequence similarities and length of the cytoplasmic loop [36,37]. 
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Human 
 
Mouse Major expressed organ or cell types 
Name 
 
Chromosomal 
locus 
Name  
Molecular mass 
nomenclature 
HUGO (Greek letter) 
nomenclature 
 Molecular mass 
nomenclature 
 
hCx23  ? mCx23 – 
hCx25 – 6 – – 
hCx26a GJB2 13q11–q12 mCx26 Breast, cochlea, placenta, 
hepatocytes, skin, pancreas, kidney, 
intestine 
hCx30 GJB6 13q12 mCx30 Brain, cochlea, skin 
hCx30.2 GJE1 7q22.1 mCx29 Brain, spinal cord, Schwann cells 
hCx30.3 GJB4 1p35–p34 mCx30.3 Skin, kidney 
hCx31 GJB3 1p34 mCx31 Cochlea, placenta, skin 
hCx31.1 GJB5 1p35.1 mCx31.1 Skin 
hCx31.9 GJC1 (GJA11) 17q21.1 mCx30.2 – 
hCx32 GJB1 Xq13.1 mCx32 Hepatocytes, secretory acinar cells, 
Schwann cells 
– – – mCx33 Sertoli cells 
hCx36 GJA9 15q13.2 mCx36 Neurons, pancreatic β-cells 
hCx37 GJA4 1p35.1 mCx37 Endothelium, granulosa cells, lung, 
skin 
hCx40 GJA5 1q21.1 mCx40 Cardiac conduction system, 
endothelium, lung 
hCx40.1 – – mCx39 – 
hCx43 GJA1 6q21–q23.2 mCx43 Many cell types 
hCx45 GJA7 17q21.31 mCx45 Cardiac conduction system, smooth 
muscle cells, neurons 
hCx46 GJA3 13q11–q12 mCx46 Lens 
hCx47 GJA12 1q41–q42 mCx47 Brain, spinal cord 
hCx50 GJA8 1q21.1 mCx50 Lens 
hCx59 GJA10 1p34 – – 
hCx62 – 6q15–q16 mCx57 Retinal horizontal cells 
Table 1.1. Connexin genes and their expression. hCx30.2 (equivalent to mouse Cx29), hCx32 and hCx43 are 
expressed in Schwann cells [38]. 
1.1.2. Domain structure of the connexins  
Connexin genes are translated to proteins that form hexameric structures in the plasma 
membrane called hemichannels or connexons, harbouring a central pore that permit the 
passage of ions and small molecules between cytoplasm and extracellular surroundings.  
Based on hydropathy plots topological model for location of different domains of connexin 
relative to the plasma membrane (Figure 1.1) was predicted [39–41]. It shows that the 
connexin polypeptide contains a short cytoplasmic amino-terminal domain (NT), four 
transmembrane domains (M1 to M4) separated by one cytoplasmic loop domain (CL) 
between M2 and M3, two extracellular loops (E1 and E2), and a carboxyl-terminal 
cytoplasmic domain (CT) [35]. The two extracellular loops are highly conserved and 
necessary for docking of two hemichannels of adjacent cells to form gap junctions. A set of 
three cysteine residues in each of the extracellular loops may help to maintain the tertiary 
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structure necessary for this docking of two hemichannels [42].  The length and sequence on 
the NT, M1-M4 are relatively conserved among all connexins. The CT has the greatest 
variability in size among connexins, from short 10-12 amino acids in Cx26, Cx30.2 and 
Cx31.1 to more than 310 amino acids in Cx59 and Cx62. The CL length also varies quite a 
lot, connexins even can be divided into three categories [43]: those that have small (30-35 aa), 
medium (50-55 aa), or large (80-105 aa) CL domains. 
 
Figure 1.1. Membrane topology of connexins. The 
cylinders, marked M1-M4, represent corresponding 
transmembrane domains. The loops between the first 
and the second, as well as the third and fourth 
transmembrane domains, are predicted to be 
extracellular (E1 and E2, respectively), each with 
three conserved cysteine residues. Both the N- and C-
termini are facing the cytoplasm [44].  
1.1.3. Connexin gene structures  
Recent studies identified 21 human and 20 mouse connexin genes in human and 
mouse genomes [45–47]. Various connexin genes are found in many different chromosomes, 
but there is a cluster of connexins in region of human chromosome 1 [48]. Genes for many 
connexins were cloned and studied by polymerase chain reaction. Collected information 
shows that many connexin genes have a similar organization and virtually all have only single 
copies in the haploid genome [47]. 
The general genomic structure of connexins is simple and consists of an untranslated 
5ʹ′-exon (exon 1) separated from a second exon (exon 2) by an intron of variable size. Exon 2 
includes the complete connexin coding region and the 3ʹ′-untranslated region (UTR) (Figure 
1.2). Recent investigations suggest that the use of multiple alternative exons to generate the 
5ʹ′-UTR may be a feature of many connexin genes, for example Cx32 and Cx36 genes [49]. 
The human Cx32 gene contains alternative first exons (containing only 5ʹ′-UTR) whose use is 
tissue specific [50,51]; some bovine Cx32 transcripts have three exons, two of which contain 
only 5ʹ′-UTR [52]. The Cx36 gene contains two exons, both of which contain untranslated and 
translated sequences. The coding region is interrupted by an intron [53–55]. It has been 
suggested that these variations in 5ʹ′-UTRs may cause differences in mRNA translation or 
stability [56,57]. 
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Figure 1.2. Structures of the connexin genes. Diagrams depict the structures of different connexin genes with 
the coding regions in dark gray boxes and the noncoding regions in white boxes. (A) Common gene structure. 
The 5ʹ′-untranslated exon 1 (5ʹ′-UTR) is separated by an intron of variable length from exon 2 harboring the 
complete coding region (shaded box) and the subsequent 3ʹ′-UTR. (B) Different 5ʹ′-UTRs can be spliced 
alternatively and/or consecutively to that exon carrying the coding region. (C) In mCx36, hCx36, mCx39, 
hCx40.1 and mCx57, the coding region is spliced.  
1.1.4. Transcriptional and translational regulation of connexin expression 
 The transcription of connexin DNAs is regulated by a variety of factors, and a lot is 
known about this process [35,38,49]. In most connexin genes the basal promoter located less 
then 300 bp upstream from the transcriptional initiation site contains binding sites for cell 
type–independent transcription factors including TATA box-binding protein, Sp1/Sp3, and 
activator protein-1 (AP-1). Binding of these factors may play a critical role in dramatic 
changes of connexins expression. For example, production of c-fos, which interacts with the 
AP-1 sites may cause the giant increase in myometrial expression of GJA1  (Cx43) mRNA 
[58]. 
 Treatment of cells with a variety of chemicals or biological substances (including 
cyclic adenosine monophosphate [cAMP], phorbol esters, and retinoids) or manipulation of 
signal transduction pathways (such as the Wnt/β-catenin/T-cell factor (TCF)/lymphocyte 
enhancer binding factor (LEF) pathway) also may regulate connexin transcription, as was 
showed before [35,38]. 
 The connexin gene promoters also contain binding sites for cell type-specific 
transcription factors. For example, multiple factors, including Nkx2.5, GATA4, and Tbx5, 
regulate GJA5  (Cx40) expression in the heart [59–61]; Nkx2.5 is an important regulator of 
genes for three connexins (Cx40, Cx43, and Cx45) in the cardiovascular system [62]. 
Importance of different transcription factors can be also shown on example of GJB1 
(Cx32). In liver and pancreas promoter P1 (8Kb upstream the start codon) is used, which 
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contains binding sites for cell type-independent transcription factors (like Sp1/Sp2 and 
nuclear factor-1 [63–65]) and cell type-specific factors (like hepatocyte nuclear factor-1 [65]). 
In Schwann cells cell-specific promoter P2, containing the early growth response gene-2 
(Egr2/Knox20) and SOX10 cell-specific factors, is used [14,66]. 
 
1.1.5. Connexin biosynthesis and posttranslational modifications 
Like all others eukaryotic trans-membrane proteins connexins are synthesized by 
ribosomes that are bound to the endoplasmic reticulum (ER) membrane [67]. They encode 
hydrophobic domains (internal trans-membrane segments) that are recognized by a signal 
recognition particle (SRP). SRP binding is necessary for docking of the 
SRP/ribosome/nascent-polypeptide-chain/mRNA complex to a protein-channel in the ER 
membrane [68]. Interesting fact is that connexins with their large hydrophobic domains are 
initially localized in the hydrophilic lumen of the translocon channel [69,70]. Once synthesis 
complete, connexins are translocated out of the channel lumen into the hydrophobic ER 
membrane environment. During this integration folding of connexin proteins is achieved. 
Different studies have demonstrated that connexin biosynthesis and membrane translocation 
follow the pathway that has been described for membrane proteins with cytoplasmically 
located N-termini [71,72]. 
Connexin oligomerization into connexons was initially reported to occur in the ER 
(Figure 1.3), however, with some exceptions [73,74]. For example, it has been showed that 
Cx43 assemble in hexamers only upon arrival in the distal regions of the Golgi complex. 
Recent data has shown that connexin oligomerization is a sequential process, which starts in 
the endoplasmic reticulum and ends upon arrival in the Golgi [75,76]. An exception to this 
pathway is Cx26, which may be either co- or post-translationally transported into the ER or 
directly to the plasma membrane, without passing through the Golgi apparatus [77]. 
When connexin oligomerization is finished connexon hemichannels are packaged into 
vesicles and transferred to the membrane. This connexon transport may either be microtubule 
dependent or independent [77]. It has been suggested that connexon insertion in the plasma 
membrane is random. However recent studies indicate that microtubules may be responsible 
for targeting of these gap junction hemichannels to specific membrane domains or even 
regions [78]. 
Upon various types of post-translational connexin modifications (like hydroxylation, 
nitrosylation, acetylation, disulfide binding and etc.) phosphorylation is the most studied [52-
55]. Phosphorylation may occur on various connexin residues and is important for proper 
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formation and functioning of gap junction channels. Although most connexins undergo these 
modifications (including Cx32) some of them, for example Cx26, remain unphosphorylated.  
 
Figure 1.3. Multiple trafficking and assembly routes of gap junctions and dual intercellular communication 
pathways. In route A, Cx32 and Cx43 are co-translationally inserted into the endoplasmic reticulum, where they 
oligomerize into connexons and are then trafficked via the Golgi to the plasma membrane. Apposition of two 
connexon hemichannels results in docking to generate a gap junction. In route B, an alternative route used by 
Cx26 does not involve trafficking through the Golgi and possibly involves post-translational insertion into either 
endoplasmic reticulum or directly into plasma membranes [79]. 
Phosphorylation is involved in the regulation of gap junctional communication at 
several stages of the connexin life cycle including hemichannel oligomerization, export of the 
protein to the plasma membrane, hemichannel activity, gap junction assembly, gap junction 
channel gating, and connexin degradation [80–82]. The effect of phosphorylation on channel 
gating is very specific, in case of Cx43 phosphorylation on different residues by the same 
kinase may lead to opposite effects. It may whether enhance or inhibit gap junction function 
and gap junction intercellular communication [77]. The phosphorylation may also affect other 
cellular functions of connexins such as control of growth and proliferation. 
 
1.1.6. Connexin mutations and disease 
Many mutations of several different connexins are associated with a wide variety of 
inherited diseases, including neuropathies, deafness, epidermal diseases, cataracts, and 
oculodentodigital dysplasia (Table 1.2). The inheritance of these diseases may be autosomal 
dominant, autosomal recessive, or X-linked [35]. 
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Disease-causing mutations have been reported to occur anywhere in the connexin 
genes. Most of identified connexin mutations are located within the protein-coding region. 
While affecting synthesis, assembly, channel function, and degradation of connexins these 
mutations may cause disease through a variety of mechanisms. Mutations can be found also in 
noncoding regions. Most probably they disrupt elements regulating transcription or interfere 
with proper splicing to generate mature connexin mRNAs. Several such mutations were found 
in Schwann cells [14,83] in GJB1 and were associated with X-linked Charcot-Marie-Tooth 
disease. More information about Cx32 mutations you can find in chapter 1.7.  
Disease Inheritance pattern 
Connexin 
Protein Gene 
Oculodendrodigital dysplasia AD (AR) Cx43 GJA1 
Cardiovascular diseases 
Atrial fibrillation AD/ND Cx40 GJA5 
Visceroatrial heterotaxia ND Cx43 GJA1 
Cataract AD Cx46 Cx50 
GJA3 
GJA8 
Myelin-related diseases 
X-linked Charcot-Marie-Tooth disease (CMTX) XR Cx32 GJB1 
Pelizaeus–Merzbacher-like disease AR Cx46.6/ Cx47 
GJA12/ 
GJC2 
Hearing loss (non-syndromic or associated with skin disorders) AR/AD 
Cx26 
Cx30 
Cx31 
GJB2 
GJB6 
GJB3 
Skin diseases AD     
Keratitis ichthyosis deafness syndrome   Cx26 Cx30 
GJB2 
GJB6 
Vohwinkel syndrome   Cx26 GJB2 
Clouston syndrome   Cx30 GJB6 
Erythrokeratodermia variabilis  Cx30·3  Cx31 
GJB4 
GJB3 
AD, autosomal dominant; AR, autosomal recessive; XR, X-linked recessive; ND, not determined. 
Table 1.2. Connexin-associated diseases and corresponding connexin proteins and genes [44]. 
1.2. Gap junctions structure 
1.2.1. Organization levels of gap junctions 
Based on the first studies of gap junctions, although they were limited to relatively 
low resolution, a model of hemichannel structure was proposed. It suggests that the 
intercellular channel is formed by the end-to-end interaction of two oligomers termed 
connexons [84]. Within these oligomers, each connexin subunit is thought to traverse the 
membrane bilayer four times, placing the amino- and carboxyl-termini on the cytoplasmic 
membrane surface [39,41,85]. Moving of transmembrane domains with respect to each other 
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may control channel opening [86]. In nature multiple gap junction channels cluster in the 
membrane and form gap junction plaques (Figure 1.4). 
 
Figure 1.4. Molecular organization and schematic topology of a gap-junctional plaque. (a): Hemichannels in 
apposed plasma membranes of neighboring cells can dock to each other and form gap junction channels. Three 
different types of gap junction have been reported - homomeric/homotypic (1), heteromeric (2) and heterotypic 
(3) - depending on their molecular composition. Homotypic or heterotypic gap junctions comprise two identical 
or two different types of hemichannel, respectively. Homomeric or heteromeric hemichannels are composed of 
one or more connexin (or possibly pannexin) isoforms, respectively. Each hemichannel represents an assembly 
of six connexin protein subunits. (b): Connexin protein subunits are tetra-spanning membrane proteins that 
share three conserved extracellular cysteine residues, which are crucial for docking. The subunits vary mainly 
in their cytoplasmic loop and C-terminal region. S–S represents conserved disulphide bonds in the extracellular 
domains of connexins [87]. 
There is a growing evidence that a single gap junction channel can be made of 
different types of connexins, i.e., two connexons each consisting of different types of 
connexins can form a heterotypic gap junction channel, whereas one connexon containing 
different types of connexins can form a heteromeric gap junction channel (Figure 1.4a). This 
hypothesis was proved by studies of fractions containing detergent solubilized gap junctions 
[16,88–90]. In general, heteromeric gap junction assembly occurs only between connexins of 
the same classes. For example, Cx32 and Cx43 translated in vitro do not form mixed gap 
junction hemichannels, but when two different connexins within the same class are 
cotranslated, they interact to form heteromeric hemichannels. 
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Distinct electrophysiological and ion selective properties have been shown not only 
for homotypic gap junction channels made of different connexins but also between homotypic 
and heterotypic gap junction channels. The net result of such diversity could provide 
communication compartments that enable a group of cells to be regulated by changes in the 
concentration of a specific second messenger or metabolite. More details can be fond in 
[38,42,79,91]. 
 
1.2.2. Electron microscopy studies of gap junction structure 
Till now electron cryomicroscopy was one of approaches that enriched our knowledge 
of gap junctions more then any other method. Recently Unger et al [20] determined the 
structure of a recombinant cardiac gap junction channel formed by Cx43 mutant (most of the 
COOH-terminal domain was truncated) by electron crystallography at resolutions of 7.5 Å in 
the membrane plane and 21 Å in the vertical direction. They showed that the recombinant gap 
junction channel formed by the Cx43 mutant was shaped like a sand glass with a thickness of 
150 Å. The outer boundary of the map revealed a tripartite arrangement that consisted of two 
membrane domains that were separated by an extracellular domain. 
 
Figure 1.5. Molecular organization of a recombinant gap junction channel. (a) A full side view is shown, and (b) 
a top view looking toward the extracellular gap is shown. For clarity, only the cytoplasmic and most of the 
membrane-spanning regions of one connexon are shown. The 24 well-resolved rod-shaped features reveal the 
packing of the transmembrane α-helices, and four have been arbitrarily labeled M1, M2, M3, and M4. Similarly, 
M1ʹ′ and M2ʹ′ identify putative a helices that are identical to M1 and M2 because of the six fold symmetry of the 
channel [20]. 
The outer diameter within the membrane region was 70 Å and in the extracellular 
portion of the channel outer diameter decreased abruptly by 20 Å (Figure 1.5a). Aqueous 
pathway narrowed from 40 to 15 Å (neglecting the contributions of amino acid side chains) in 
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proceeding from the cytoplasmic to the extracellular side of the bilayer. Which was caused by 
the tilt of the channel-lining M3 α-helix (Figure 1.5b). The aqueous pathway then widened 
again to a diameter of 25 Å within the extracellular vestibule. 
Because the connecting loops between the transmembrane α-helices could not be 
revealed with such low resolution (in-plane resolution of 7.5 Å), there was ambiguity in 
assigning the molecular boundary of the connexin subunit. But earlier it was already 
demonstrated that extracellular loops E1 and E2 are involved in initiating the interaction 
between connexons in adjacent cells (while using site directed mutagenesis to shift four of the 
six conserved cysteines in the extracellular loops of Cx32 individually, in all possible 
pairwise combinations, and even in some quadruple combinations Foote et al studied 
connexons coupling [92]). 
 
1.2.3. X-Ray diffraction analysis of gap junction structure 
More precise knowledge was obtained from X-Ray diffraction patterns of Cx26 
crystals with resolution 3.5 Å by Maeda et al in 2009 [10]. They confirmed size dimensions 
had been received earlier by electron crystallography having in mind that side chains were not 
visible with 7 Å resolution. 
Connexin 26 consists of four transmembrane segments (M1-4), two extracellular loops 
(E1 and E2), a cytoplasmic loop, an N-terminal helix (NT), and a C-terminal segment (Figure 
1.6). Any pair of adjacent helices of Cx26 is antiparallel, forming a typical four-helix bundle. 
M1 and M2 face the interior, whereas M3 and M4 face the hydrophobic membrane 
environment. M1 is identified as a major pore-lining helix (before there has been a 
disagreement, one was assuming M3 playing role of major pore-lining helix [18,93], while 
others – M1 [94,95]). Pore diameter narrows from the cytoplasmic to the extracellular side of 
the membrane because M1 is canted. First transmembrane domain ends in a short 310-helix. 
M2 is kinked at Pro87 (Pro87Leu mutation has been shown to cause an abnormal gating [96]) 
and M2 and M3 protrude into the cytoplasm. M4 is tilted from the molecular axis by about 
30°. This results in extension of connexon diameter on the intracellular side. 
The extracellular loop E1 contains a 310-helix at the beginning and a short α-helix in 
its C-terminal half. E2, together with E1, contains a short antiparallel β-sheet and stretches 
over E1, forming the outside wall of the connexon. Six conserved cysteine residues, three in 
each loop, form intramolecular disulphide bonds between E1 and E2. The N-terminal half of 
E2 is flexible and its amino-acid sequence varies greatly among connexins [10]. The C-
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terminal half of E2 begins with a 310 turn and is followed by a conserved Pro-Cys-Pro motif 
that reverses its direction back to M4. 
 
Figure 1.6. Topological diagram of the Cx26. Open boxes indicate regions with a helical secondary structure 
denoted as NT, M1, M2, M3, M4, 310-helix and short helix in E1. The membrane region is depicted in light blue. 
Red lines indicate ten-amino-acid increments. Color code: white letters in black circles: disordered residues; 
white letters in grey circles: residues whose side-chains are not included in the model; green: methionine 
residues; yellow: extracellular cysteine residues that form disulfide bonds; purple: residues mediating intra-
connexin interactions; red: residues mediating inter-connexin interactions; blue: residues mediating inter-
connexon interactions [10]. 
Most of the prominent intra-connexin interactions are in the extracellular part of the 
transmembrane region. Arg32 (M1) interacts with Gln80 (M2), Glu147 (M3), and Ser199 
(M4). Two hydrophobic cores around Trp44 (E1) and Trp77 (M2) stabilize the connexin 
structure. Ala39 (M1), Ala40 (M1), Val43 (E1) and Ile74 (M2) contribute to the first 
hydrophobic core around Trp44, and Phe154 (M3) and Met195 (M4) form the second core 
with Trp77 (Figure 1.7). In the intracellular part of the transmembrane region, Arg143 (M3) 
forms hydrogen bonds with Asn206 (M3) and Ser139 (M3) (Figure 1.7). 
Interactions between connexins in single hemichannel are mostly located in the 
extracellular half of M2 and M4 and in the extracellular loops. Glu47 (E1), Gln48 (E1), 
Asn62 (E1), Asp66 (E1), Tyr65 (E1), Arg75 (TM2) and Ser72 (E1) from one connexin, and 
Asp46 (E1), Asp50 (E1), Arg184 (E2) Thr186 (M4) and Glu187 (M4) from the adjacent 
connexin form the core of the inter-connexin interactions. Although M3 is evolutionarily 
more variable than the other three helices, every third or fourth residue in M3 is aromatic, 
generating an aromatic face that is conserved among connexins. Each helix in a connexin 
contributes to an aromatic cluster in the groove between two adjacent connexins. Most of the 
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residues involved in intra- and inter-connexin interactions are conserved within the connexin 
family [10], and mutations of these residues are associated with different disorders [97]. Most 
probably these mutations affect proper folding and oligomerization of connexins. 
 
 
Figure 1.7. Intra-connexin interactions in the Cx26. The Cα trace is shown in ribbon or line representation and 
the side-chains in the close-up views in the boxes are shown as sticks. Hydrogen bonds or salt bridges are shown 
as dotted lines [10].  
Both E1 and E2 are involved in the interactions between the two adjoining connexons 
of the gap junction channel (Figure 1.8). In E1, Asn54 forms hydrogen bonds with Leu56 in 
the opposite connexin, and Gln57 forms symmetric hydrogen bonds with the same residue of 
the diagonally opposite connexin. Both residues are highly conserved among connexins. In 
E2, Lys168, Asp179, Thr177 and Asn176 form hydrogen bonds and salt bridges with the 
opposite connexin. Forming a tight double-layered wall these interactions connects the two 
adjoining hemichannels and separates the channel pore from the extracellular environment. 
The pore of a gap junction channel consists of an intracellular channel entrance, a pore 
funnel and an extracellular cavity. Intracellular parts of M2 and M3 form the channel 
entrance. The short NTs of the six connexins are imbedded into the pore, forming the funnel. 
N-terminal residues Asp2, Trp3, Thr5, Leu6 and Ile9 line the funnel surface. Asp2 forms 
hydrogen bonds with Thr5 from the neighboring connexin (Figure 1.9). Trp3 forms 
hydrophobic interactions with Met34 (M1) of the neighboring connexin, which draws the NT 
to the inner wall of the channel. This interaction maintains the funnel in the open state, with 
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an inner diameter of 14 Å. While Met34Thr mutation is reported to form structures 
indistinguishable from wild type gap junctions, it decreases electrical current [98,99] by 
disrupting the interaction of the NT with Trp3 and narrowing the funnel [100].  
 
 
Figure 1.8. Intercellular interactions. The connexins forming 
the gap junction channel are labeled A to F and A' to F'. The 
right top and bottom boxes show intercellular interactions in 
E1 and E2, respectively [10]. 
 
Cx26 is known to be closed by an inside positive potential. On the other hand Cx32 
has Asn at position 2 and closes after an inside negative potential [101]. A cytoplasmic 
movement of the N-terminus, where the voltage sensor is believed to reside, has been 
suggested to initiate voltage-dependent gating [101–103]. Although NT plays a major role in 
this model of voltage-dependent gating (in agreement with previous physiological studies 
[102–104]) it is possible that the invisible cytoplasmic loop or the C terminus might 
contribute as a component of the plug, as was described earlier in case of Cx43 [105–107]. 
 
Figure 1.9. The six NTs form a funnel structure, which is stabilized by a circular network of hydrogen bonds 
between Asp2 and the main chain of Thr5. The connexins are shown in line and the NTs in ribbon representation 
superposed on a surface representation. The close-up view shows the interaction between the ring of Trp3 and 
the methyl group of Met34 (M1) in the adjacent connexin (hydrophobic interaction: orange broken line; 
hydrogen bond: red broken line) [10]. 
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1.3. Gating mechanisms of gap junctions and their permeability 
1.3.1. Connexins voltage sensitivity 
Like many others ion channels gap junction channels are voltage dependent, but the 
magnitude of the dependency varies greatly among connexin family. Connexin channels 
exhibit complex channel sensitivity, the conductance (Gj) of most of them is sensitive to 
transjunctional voltage (Vj, the voltage difference between two cell interiors coupled by gap 
junctions), but many are also sensitive to membrane potential (Vm, a cell absolute inside-
outside voltage) [108]. It is hypothesized that this dual voltage regulation is due to the 
existence of two different gates, each of which specifically senses one type of voltage [109]. 
The Gj of most homotypic connexin channels is typically maximal at Vj =0 (Gjmax) and it 
decreases symmetrically for positive and negative Vj pulses tot non-zero conductance values. 
Transitions between the main open state and the closed state could be either fast or slow. 
Accordingly, these two gating processes have been termed “fast Vj-gating” and “slow Vj-
gating” respectively. Little is known about the mechanisms responsible for slow Vj-gating but 
there are evidences that the C-terminal domain is involved in the fast Vj-gating, as it is 
abolished when this domain is truncated [110] or fused to a large molecule like GFP [111], 
and it is recovered when truncated connexins are coexpressed with C-terminal domains [112].  
It is hypothesized that the fast Vj gating can be explained by the “ball-and chain” model, 
where the displacement of the C-terminal domain toward the inner mouth of the channel pore 
would physically close the pore, a model that had already been proposed for the closing state 
triggered by pH [113], Insulin and IGFs [114]. Nano metric data using AFM also support this 
model [115]. 
Connexins sensitive to Vm have also a slow Vm-gating mechanism. This mechanism 
would regulate electrical coupling when Vj=0, especially in excitable cells. The slow Vm-
gating has been also related to the C-terminal domain, but to the residues close to fourth 
transmembrane domain [116]. These findings suggest that an outwardly directed movement of 
the voltage sensor, which would lead to conformational changes that close the pore, mediates 
slow Vm-gating.  
On the other hand recent structural studies of Cx26 have proposed Vj-gating model in 
which N-terminus is a major sensing particle and is forming the plug to clothe the pore 
(Figure 1.10) [10]. Although this model is not valid for other voltage-sensitive ion channels 
containing the S4 helix as a voltage sensor [117], it is in good accordance with previous 
physiological studies [102–104]. Also it has been reported that the Cx37 channels with 
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truncated N-terminus showed no electrical function [118]. At present there is no appropriate 
structural model about how such Cx37 channels are totally closed and more detailed structural 
information for gap junctions is required to explain voltage gating of the whole connexin 
protein family. 
 
Figure 1.10. Modified plug-gating model for voltage-dependent gating of the gap junction channel. Left: 
Model of the Cx26 gap junction channel in the open state at Vj = 0. NT (red) is attached to the channel (blue) 
by the hydrophobic interaction between Trp3 and Met34, keeping the channel open. Right: Model of the Cx26 
gap junction channel in the closed state. Relative potential gradient is depicted as Vj > 0 when the upper cell is 
more positive than the lower. The NTs of the connexon at the inside positive potential are released from the 
hydrogen bond network and the Met34 hook shown in the left side, resulting in the formation of a plug [10]. 
1.3.2. Chemical gating of gap junctions 
Ca2+ was the first cytoplasmic factor showed to be involved in the regulation of gap 
junction function [119]. Later DeVries and Schwartz [120] reported that cultured solitary 
horizontal cells of the catfish retina express an endogenous current mediated by hemichannels 
that open upon reduction of the extracellular Ca2+.  The current is reduced by external Ca2+ 
higher than 1 mM, treatment with dopamine, or a weak acid that corresponds to the blockade 
of Lucifer yellow uptake. Subsequently, the electrophysiological characterization of 
macroscopic and single hemichannel currents has been reported for various connexins [49]. 
Based on electron microscopic studies it has been proposed that Ca2+ induces a regional 
closure of the pore [121]. 
Agonists of hemichannel opening have also been described. For example antimalaric 
drugs quinidine and quinine enhance hemichannel-mediated currents in retinal horizontal cells 
bathed in low extracellular Ca2+ [122]. Also alendronate (used in the treatment of bone 
diseases) induces opening of hemichannels formed by Cx43 [123]. 
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Opening of Cx43 hemichannels can be blocked by activation of a PKC-dependent 
pathway [124,125]. This proves that protein phosphorylation is involved in gating process. 
Closure of hemichannels has been observed after extracellular application of lanthanide 
cations, La3+ [126], or Gd3+ [127], or treatment with gap junction channel blockers, such as 
octanol, heptanol, carbenoxolone, oleamide, halothane, and 18-α- and 18-β-glycyrrhetinic 
acid. 
Extracellular acidification (pH reduction) also closes hemichannels formed by various 
connexins [49]. Cx43 is the best-studied example of pH gating. In its case it have been shown 
that gating in response to pH changes is caused by interactions between C-terminus and 
specific segment of CL [113]. Expression of truncated Cx43 (Cx43M257Δ) prevents 
acidification-induced uncoupling, while if the truncated portion of the CT is coexpressed as a 
separate peptide uncoupling could be restored [128]. Based on these data the model has been 
proposed where the CT domain acts as a gating particle. At normal pH, the gating particle is 
away from the pore and the channel is open. Upon acidification, the particle binds to a 
separate region of the protein (a receptor) affiliated structurally or functionally with the pore. 
This particle-receptor interaction leads to channel closure.  
NMR studies of Cx43CT indicated reduced mobility of this domain at low pH due to 
its oligomerization [129]. Further studies demonstrated that the Cx43CT formed dimer in a 
pH-dependent manner [130]. These results led to the suggestion that dimerization of the CT 
may be one of the structural changes involved in the pH regulation of Cx43. Additionally, the 
change in oligomeric state of the CT may play a role in modulating the molecular partners 
that associate with Cx43 under a given condition, thus acting as a switch for modifications in 
channel function. 
Unfortunately this particle-gating model cannot be accepted for the whole connexin 
family. It was shown that pH sensitivity varies greatly among connexins [112]. Differences 
were attributed to the diversity of the primary sequence, particularly in regulatory domain 
regions like the CT. Although some connexins follow the basic particle-receptor model of pH 
gating [112] there are exceptions - Cx26, Cx32, and Cx46. All three are not affected by the 
truncation of their CTs. Studies on Cx46 by Trexler et al suggest that pH gating of that 
connexin involves direct protonation of the connexin molecule [131].  
In case of Cx26 and Cx32 pH-dependent closure was shown when hemichannels were 
exposed to aminosulfonate buffers (HEPES, MES) [132]. However, pH-dependent channel 
gating was not seen when non-aminosulfonate buffers were used. At constant pH, increased 
aminosulfonate concentration caused hemichannel closure. Similar effects were seen with 
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taurine, the most common cytoplasmic aminosulfonate, at physiological concentrations. Thus, 
the possibility arises that acidification-induced effects on these channels may actually be 
mediated through protonation of cytoplasmic regulators. 
High-resolution atomic force microscopy showed that the Cx26 pore diameter 
increased in response to pH growing in HEPES buffer [133]. Pore diameter incensement was 
caused by approximately 6.5° rotation in lobes at the extracellular surface of the 
hemichannels. These transitions suggest a modification of the Cx26 pore structure during pH 
gating.  
 
1.3.3. Permeability of connexin channels 
Connexin channels like many other channels possess an aqueous pore through with ions 
can flow. It can be stated that the molecular weight of substances being allowed to cross the 
junction should be less than 1kD as suggested by certain experiments with dye molecules 
[134]. The permeability of gap junctions is widely non-selective allowing the pass of small 
molecules (charged or not), second messengers and small metabolites. On the other hand gap 
junctions are impermeable to nucleic acids and proteins [37]. In summary, their pore 
selectivity is not uniquely defined in contrast to ion channels. 
Using standard electrophysiological techniques unitary conductance of gap junctions 
was studied. It was varying greatly among connexin family members starting from 9 pS in 
case of Cx31.9 up to 350 pS for Cx30 [35]. Since connexin channels are generally permeable 
to molecules at least 8 to 10 Å in minimal diameter it have been presumed that connexin 
channels would not have significant charge selectivity. Direct measurements showed opposite 
picture (Table 1.3) [35]. The vastly different unitary conductance’s and charge selectivity’s 
suggest that the pores of connexin channels have diverse properties - structural and 
electrostatic. 
Connexin Conductance ratio cation/anion Permeability ratio cation/anion 
Cx26 2.6  
Cx32 0.94 0.77 
Cx37 2.3-3.4  
Cx40 4.5 6.2-6.9 
Cx43 1.3 1 
Cx45 10  
Cx46  7-10.3 
Cx50 2.4  
 
Table 1.3. Charge selectivity to atomic ions [35] 
 28 
In several studies the limiting pore width of connexin channels was measured by 
observation of relatively unreactive molecules (e.g., sugars, polyethyleneglycols) propagation. 
These studies showed that PEGs 400 Da and larger could not enter the pores but PEGs 
300 Da and smaller were able to enter the pores [135]. In case of Cx32 channels this cutoff 
size was between PEG400 and PEG300 [136]. Based on these studies the ranking of limiting 
pore diameter can by build: Cx43 (90 pS) > Cx32 (50 pS) > Cx26 (130 pS) = Cx26/Cx32 (48 
to 89 pS) > Cx37 (300 pS) and Cx43 (90 pS) ≈ Cx46 (140 pS) > Cx40 (180 pS) [137,138]. To 
summarize it is obvious that channels with the narrowest pores are more charge selective than 
channels with wider pore diameters. 
It was showed that some types of connexin channels can transfer second messengers, 
amino acids, nucleotides, Ca2+, and glucose and its metabolites [35,139,140]. However 
permeability for big molecules (both biological and non-biological) also varies a lot for 
different connexins [141,142]. From these studies it is clear that gap junction channels can 
have some affinity selectivity mechanisms that are highly specific for certain permeants, and 
whose properties cannot be extrapolated in a straightforward way from estimates of pore size, 
conductance or charge selectivity, or even from known permeants [143,144]. 
 
1.4. Charcot-Marie-Tooth disease and connexin 32 mutations 
Charcot-Marie-Tooth (CMT) disease was first described by neurologists Jean Martin 
Charcot, Pierre Marie and Howard Henry Tooth in 1886. This is a group of inherited 
peripheral neuropathies that affect both motor and sensory nerves and has a high prevalence 
among the population (1:2500). Although CMT is characterized by distal muscle weakness 
and atrophy and foot deformities as claw toes (Figure 1.11), it is nowadays classified into 
different variants according to clinical, electrophysiological, histopathological and genetic 
features [108]. 
 
Figure 1.11. The foot of a person with 
Charcot–Marie–Tooth disease. The lack of 
muscle, a high arch, and claw toes are signs of 
this genetic disease. 
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The X-linked form of CMT disease  (CMTX) is the most common form of hereditary 
sensory and motor neuropathy [145,146]. The clinical course is characterized by slowly 
progressive symptoms, such as distal muscle weakness and atrophy, areflexia, and variable 
sensory abnormalities. While affected males have moderate to severe symptoms, 
heterozygous females are usually mildly affected or even asymptomatic. In 1993 Bergoffen et 
al. [147] first associated mutations in GJB1, the gene encoding the gap junction protein 
connexin 32, with CMTX. Since then more than 290 different disease-causing mutations of 
Cx32 have been described. CMTX patients have nerve conduction deficits [148] due to 
axonal loss in peripheral nerves, partially failed regeneration, and myelin abnormalities [149–
151]. Although mutant proteins are expressed in Schwann cells but not in axons, it is 
suggested that CMTX develops because these Schwann cell cannot provide metabolic support 
for normal axonal function. 
 
Figure 1.12. The structure of the human Cx32 protein and some disease-causing mutations. The consequences of 
the known CMTX mutations are shown schematically, along with the localization of 51 different Cx32 mutants 
in transfected mammalian cells [152]. 
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Different types of Cx32 mutations may cause CMTX, including missense (amino acid 
substitutions), nonsense (premature stop), deletions, insertions, and frame-shift mutations 
(Figure 1.12). Most of these mutations lead to loss of Cx32 function due to absence of entire 
Cx32 coding region [153], changes in cell-cell channel gating and permeability [154–156] or 
loss of channel-forming ability [146,152,157]. 
In the meantime some several CMTX mutations were showed to lead to toxic gain of 
Cx32 function. For example S85C [158] and F235C [159] mutants of Cx32 form abnormally 
active functional hemichannels in Xenopus oocytes that may lead to loss of metabolites and 
ions in Schwann cells. 
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List of Abbreviations 
A8-35  amphipol A8-35 
AcP  acetyl phosphate, potassium salt 
AIM  auto-induction media 
APS  ammonium persulfate 
BR  bacteriorhodopsin 
Brij  nonionic polyoxyethylene surfactant 
BSA  bovine serum albumin 
CMC  critical micelle concentration 
DDM  n-Dodecyl-β-D-Maltopyranoside 
DM  n-Decyl-β-D-Maltopyranoside 
DMSO  dimethyl sulfoxide 
DTT  dithiothreitol 
EDTA  ethylenediaminetetraacetic acid 
Fos  n-Dodecylphosphocholine 
GPCR  G protein coupled receptor 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
MTAB  myristyltrimethylammonium bromide 
NLS  sodium lauroyl sarcosinate 
OG  octyl-β-glucopyranoside 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
PEP  phosphoenol-pyruvic-acid, mono-potassium salt 
RNasin RNase inhibitor 
SDS  sodium dodecyl sulfate 
TEMED tetramethylethylenediamine 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Organisms 
Used E.coli strains are listed in the Table 2.1. 
Strain Relevant genotype Source 
Escherichia coli TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 
araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(StrR) endA1 λ- 
Invitrogen 
Escherichia coli BL21 
(DE3) 
fhuA2 [lon] ompT gal (λ DE3) [dcm] 
∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
New England 
BioLabs 
Escherichia coli C43 (DE3) F - ompT gal dcm hsdSB (rB- mB-) (DE3)  Lucigen 
Escherichia coli Lemo21 huA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS/ 
pLemo(CamR) 
 λ DE3 = λ sBamHIo ∆EcoRI-
B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
pLemo = pACYC184-PrhaBAD-lysY 
New England 
BioLabs 
Escherichia coli SE1 F-, CmR, ompT, lon, hsdSB (restriction-, 
modification-), gal, dcm, DE3 (lacI, 
T7polymerase under the control of the 
PlacUV5 promoter), ccdB+. 
Delphi 
genetics 
 
Table 2.1. List of organisms used in this work. 
2.1.2. Vectors 
Used vectors with main features are listed in Table 2.2. Below, on Figure 2.1, you can find 
their maps. 
Vectors Relevant features Source 
pSCodon1.2 T7 promoter, His C-terminal tag, ccdA, Amp resistance, lacI 
repressor 
Delphi 
genetics 
pivex2.3d T7 promoter, His C-terminal tag, high copy number, Amp 
resistance 
5 Prime 
pivex2.4d T7 promoter, His N-terminal tag, high copy number, Amp 
resistance 
5 Prime 
pKM586 tetO promoter, TEV protease  S219D mutant, Kn resistance, 10 
copies per cell 
Addgene 
pRK603 tetO promoter, TEV protease S219D mutant, Kn resistance, 30 
copies per cell 
Addgene 
 
Table 3.2. List of vectors with main features used in this work. 
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Figure 2.1. Maps of vectors pSCodon1.2, pivex2.3d and pivex2.4d with common features and main cloning 
sites.  
2.1.3. Oligonucleotides used for Cx32 cloning 
Cloning of Cx32 into an expression vectors was based on a site-directed mutagenesis 
strategy. Human Cx32 gene was amplified from pMA_Cx32 plasmid (obtained from Dr. 
Carsten Zeilinger) by PCR and cloned into pSCodon1.2 vector containing already MstX gene 
(Membrane-integrating protein MstX from Bacillus subtilis). Modifed pSCodon1.2 recipient 
vectors were earlier produced by Taras Balandin and Maria Silacheva in our laboratory. 
Optimized Cx32 gene for E.coli expression was synthesized by MWG, Ebersberg, 
Germany. 
The following primers were used to generate constructions used in this work:  
frwBamHINdeIhCx32 5ʹ′-ttggatcccatatgaactggacaggtttgtacaccttgc-3ʹ′ 
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frwBamHEKCx32 5ʹ′-gcggatccgacgatgacgacaaaatgaactggacaggtttgtacaccttg-3ʹ′ 
frwBamHTrCx32 5ʹ′-gcggatccctggttccgcgtggtagctggacaggtttgtacaccttgctc-3ʹ′ 
frwBamHTrhCx32 5ʹ′-gcggatccctggttccgcgtggatgaactggacaggtttgtacaccttgctc-3ʹ′ 
frwAgeIFXaCx32 5ʹ′-ggcaccggttattgaaggtcgtatgaactggacaggtttgtacacc-3ʹ′ 
frwAgeITevhCx32 5ʹ′-cgcaccggttgagaatctttattttcagggcatgaactggacaggtttgtacacc-3ʹ′ 
frwNdeIohCx32 5ʹ′-gagatatacatatgaattggaccggtctgtataccctgc-3ʹ′ 
frwM1GCx32 5ʹ′-aggccgcggcaattggaccggtctgtataccctgc-3ʹ′ 
frw_AT_H6 5ʹ′-atgaaatattataaatattatcatcatcatcatcatcatagcagcggc-3ʹ′ 
frw_SER_H6 5ʹ′-atgaaatcatcatcatcatcacatcatcatcatcatcatagcagcggc-3ʹ′ 
frw_G_H6 5ʹ′-atgaaaagtaaaggagaagaacatcatcatcatcatcatagcagcggc-3ʹ′ 
frw_H_H6 5ʹ′-atgaaaccatacgatggtccacatcatcatcatcatcatagcagcggc-3ʹ′ 
revBamHICx32 5ʹ′-tttcggatccgcaggccgagcagcggtcgctcttttcagc-3ʹ′ 
revXhoIhCx32 5ʹ′-ttctcgagttattagcaggccgagcagcggtc-3ʹ′ 
revBsrgIhCx32Tev 5ʹ′-aggtgtacaaacctgtccagttcatgccctgaaaataaagattctcaaccggtgcg-3ʹ′ 
revXhoIohCx32 5ʹ′-tcgctcgagttattaacatgcgctacaacgatcgcttttttctg-3ʹ′ 
rev_RBS_T7 5ʹ′-ggtatatctccttcttaaagttaaacaaaattatttctagaggg-3ʹ′ 
2.1.4. Chemicals 
Non-organic salts and acids were bought from Sigma-Aldrich, Applichem and Merck. 
Detergents and lipids – from Sigma-Aldrich, Affimetrix and Avanti Polar Lipids. 
Components of cell free expression system – from Sigma-Aldrich, Roth and Roche. DNA 
modifying enzymes – from Thermo. Factor Xa protease – from Qiagen, enterokinase – from 
New England Biolabs, thrombin – from Sigma-Aldrich. 
 
2.2. Methods 
2.2.1. Molecular biology methods 
2.2.1.1. Transformation of plasmids into E.coli cells 
Competent cells were prepared as described earlier [160]. Briefly TOP10 E.coli cells 
were grown in 50 ml of LB medium (1% Trypton, 0.5% Yeast extract, 1% NaCl, pH 7.0) in 
500 ml flask at 37°C with vigorous shaking to the early exponential phase (OD600 0.3-0.4). 
Then the cells were pelleted by centrifugation at 1000×g for 10 min at 4°C and resuspended at 
one-tenth of their original volume in ice-cold TSS solution (LB broth with 10% PEG8000, 
5% DMSO, 50mM MgCl2, pH 6.5). 0.1-ml aliquots of the cells were transferred into cold 
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polypropylene tubes and frozen in liquid nitrogen. The frozen competent cells were stored 
at -80°C. 
For transformation a plasmid solution (2 µl) or ligation mixture (10 µl) were added to 
0.1-ml aliquot of competent cells and kept on ice for 1 h. Then the heat pulse was applied at 
42°C for 1 min with gentle stirring. After that the cells were incubated on ice for additional 
15 min. Next, 0.5 ml of LB broth was added, and the cells were grown at 37°C with shaking 
(180 rpm) for 1h to allow expression of the antibiotic-resistance gene. The bacteria were 
stroke on agar plate containing appropriate antibiotics (1% Trypton, 1% Yeast extract, 
0.9% NaCl, 2% glucose, 1.5% agar, pH 7.0 and 50-100 mg/ml appropriate antibiotic). The 
plate was incubated overnight at 37°C. 
 
2.2.1.2. Plasmid DNA isolation 
For plasmid DNA isolation the separate colony was grown overnight in 20 ml of LB 
medium in 100 ml flask at 37°C with shaking (180 rpm). The bacteria were pelleted by 
centrifugation at 5000×g for 10 min at 4°C and resuspended in 0.5 ml Buffer A1 from 
commercial NucleoSpin® Plasmid purification kit (Macherey-Nagel, Dueren, Germany). 
Next, the bacteria were processed by SDS/alkaline lysis (addition of 0.5 ml Buffer A2). High-
salt Buffer A3 (0.5 ml) was added to neutralize the lysate and to create appropriate conditions 
for DNA binding to the silica membrane. After centrifugation at 10000×g for 10 min at 4°C 
the clear supernatant was loaded onto a NucleoSpin® Plasmid spin column. Contaminations 
like salts and macromolecular cellular components were removed by simple washing with 
0.6 ml ethanol-containing Buffer A4. After that additional washing with 0.6 ml Buffer AW 
was done. The plasmid DNA was eluted in 50 µl slightly alkaline Buffer AE (5 mM Tris-HCl, 
pH 8.5) and stored at -20°C. 
 
2.2.1.3. Plasmid DNA purification for cell free protein synthesis 
For in vitro protein expression high quantity of pure plasmid matrix is needed. That is 
why the special protocol was used. Briefly, the separate colony was grown overnight in 35 ml 
of LB medium in 500 ml flask at 37°C with shaking (180 rpm). The bacteria were pelleted by 
centrifugation at 5000×g for 10 min at 4°C and resuspended in 4 ml Buffer P1 from 
commercial Qiagen® Plasmid Plus Midi Kit (Qiagen, Hilden, Germany). Next, 4 ml of lysis 
Buffer P2 was added and the mixture was incubated for 3 min at room temperature. High-salt 
Buffer S3 (4 ml) was added to neutralize the lysate and to create appropriate conditions for 
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DNA binding to the silica membrane. The mixture again was incubated for 10 min at room 
temperature and then filtered through QIAfilter Cartridge. 2 ml of Buffer BB was added to the 
clear lysate. The mixture was loaded onto Qiagen Plasmid Plus spin column. To wash the 
DNA 0.7 ml Buffer ETR and 0.7 ml Buffer PE were used. The pure plasmid DNA was eluted 
in 100 µl Buffer EB and stored at -20°C. 
 
2.2.1.4. Amplification of Cx32 gene. 
DNA fragments were amplified by PCR. 50 µl of the reaction mixture contained 50 ng 
of DNA matrix, 150 pmol of each primer, 20 nmol of each dNTP’s, 0.5 U Phusion Hot Start 
II DNA Polymerase (Thermo, USA) and 10 µl of Phusion HF Buffer or Phusion GC Buffer. 
In case of whole plasmid PCR, additives were used – 2% DMSO and 75 nmol MgCl2. 
The amplification of DNA in the thermocycler was done in two-step manner following 
next scheme: 
2’ at 98°C 
20” at 98°C 
30” at primers’ melting temperature minus 3-5°C repeat 5 times 
40” at 72°C 
20” at 98°C 
30” at primers’ melting temperature repeat 35-40 times 
40” at 72°C 
10’ at 72°C  
Stay at 4°C 
In case of whole plasmid PCR elongation time at 72°C was increased to 2 min in each cycle. 
 
2.2.1.5. PCR products analysis and purification 
The PCR products were analyzed by horizontal agarose gel-electrophoresis. DNA 
probes, mixed with DNA loading buffer (Thermo, USA) in 1:5 dilution, were loaded onto 
0.7-1.5% agarose gels running in TAE buffer (40 mM Tris-base, 1 mM EDTA, acetic acid till 
pH reaches 8.0). Staining of DNA bands was done by adding GelRed (Biotium) in 1:10000 
dilution to TAE buffer. The DNA fragments were separated by applying 9 V/cm voltage to 
the gel. The bands of interest were catted out and NucleoSpin® Gel and PCR Clean-up kit 
(Macherey-Nagel, Dueren, Germany) was used for DNA extraction. Briefly, the agarose gel 
slice was dissolved in high-salt Buffer NT and applied to a NucleoSpin® Gel and PCR Clean-
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up Column followed by centrifugation and a subsequent washing step with ethanol-containing 
Buffer NT3. The pure DNA was eluted under low ionic strength conditions with slightly 
alkaline Buffer NE (5 mM Tris-HCl, pH 8.5). 
 
2.2.1.6. DNA restriction and plasmids linearization 
PCR products and plasmids were cut with corresponding restriction enzymes by 1 h 
incubation at 37°C. Usually FastDigest® restriction enzymes from Thermo were used together 
with FastDigest® buffer. Restriction enzymes were inactivated by 20 min incubation at 60-
85°C. 
Plasmids, used further for ligation, were incubated with 1 U Thermosensitive Alkaline 
Phosphatase (Thermo, USA) for 30 min at 37°C after restriction enzymes inactivation. 
 
2.2.1.7. Ligation of DNA 
For ligation of the DNA fragments T4 DNA Ligase (Thermo, USA) was used. 100 ng 
of recipient vector DNA were mixed with excess amount of insert DNA (5-10 times excess) 
and 1 U of T4 DNA Ligase in ligase buffer. The ligation mixture was incubated overnight at 
20°C and then used for transformation or stored at -20°C. 
 
2.2.2. Cell free (CECF) expression of Cx32 
2.2.2.1. E.coli S30 extract preparation 
E.coli S30 extract was prepared by Vitaly Shevchenko in our laboratory by the 
procedure described earlier [161,162]. Briefly, fresh overnight culture from E.coli strain 
BL21 Star in TB medium (1.2% Trypton, 2.4% Yeast extract, 0.5% Glycerol, 17 mM 
KH2PO4, 72 mM K2HPO4) was used to inoculate 10 L of TB medium in a fermenter at a 
ration 1:100. The cells were incubated at 37°C with vigorous stirring and good aeration till 
they reached the mid-log phase corresponding to an OD600 of 3.5. Fermenter heating was 
switched off and the broth was chilled down to 6°C as quickly as possible (around 30 min). 
Final OD600 of the broth after cooling was around 4.5. The cells were harvested by 
centrifugation at 4°C for 10 min at 5000×g in precooled beakers. The pellet was resuspended 
in 100 ml of S30-A buffer (10 mM Tris-acetate, 14 mM Mg(OAc)2, 6 mM β-
mercaptoethanol, 0.6 mM KCl, pH 8.2) precooled to 4°C. The suspension was centrifuged at 
8000×g at 4°C for 10 min. Washing step was repeated two more times. After that the pellet of 
wet bacterial cells was resuspended in equal volume (for 65g cells 65 ml of buffer were used) 
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of S30-B buffer (10 mM Tris-acetate, 14 mM Mg(OAc)2, 0.6 mM KCl, 1 mM DTT, 0.1 mM 
phenylmethanesulfonyl fluoride, pH 8.2) precooled to 4°C. The cells were disrupted by 
passing through the microfluidizer (M110-P, Microfluidics, Newton, USA) precooled at 4°C 
with one pass. The cell debris was pelleted by centrifugation at 30000×g at 4°C for 30 min. 
Upper two-third of the supernatant was transferred in a clean tube and centrifugation step was 
repeated. Again upper two-third of the supernatant was removed, NaCl was added till final 
concentration of 400 mM and the solution was incubated at 42°C for 45 min in a water bath. 
Next the solution was dialyzed (dialysis membrane cut-off 14 kDa) at 4°C against 60 vol of 
S30-C buffer (10 mM Tris-acetate, 14 mM Mg(OAc)2, 0.5 mM DTT, 0.6 mM KOAc, 
pH 8.2). After 2 h the dialysis buffer was exchanged and dialysis was continued overnight. 
After that the extract was centrifuged at 30000×g at 4°C for 30 min. The clear supernatant 
was removed; 0.5-ml aliquots were transferred into cold polypropylene tubes and frozen in 
liquid nitrogen. The frozen extract was stored at -80°C. 
 
2.2.2.2. T7 RNA polymerase expression and purification 
Since T7 RNA polymerase is the most expensive component of cell protein synthesis 
reaction and has to be applied at relatively high amounts it was produced in our laboratory by 
the simplified protocol described earlier [161]. Briefly, 4 L of LB medium with 100 mg/l 
ampicillin was inoculated with a fresh overnight LB culture of BL21 Star containing 
pAR1219 plasmid at a ratio 1:100. The bacteria were cultured in 2 L flasks at 37°C with 
vigorous shaking (120-150 rpm) until OD600 of 0.6 was obtained. Then T7 RNA polymerase 
expression was induced with IPTG of 1 mM final concentration and the bacteria were further 
incubated at 37°C for 5 h. The cells were harvested by centrifugation at 5000×g for 20 min at 
4°C and resuspended in 120 ml of T7 buffer (30 mM Tris, 10 mM EDTA, 50 mM NaCl, 
5% Glycerol, 10 mM of β-mercaptoethanol, pH 8.0). The cells were disrupted by passing 
through the microfluidizer precooled at 4°C with one pass. The cell debris was pelleted by 
centrifugation at 20000×g for 30 min at 4°C. The supernatant was adjusted to a final 
concentration of 2% streptomycin sulfate by gentle stirring and dropwise addition of a 10% 
streptomycin sulfate stock solution. Precipitated DNA was removed by centrifugation at 
30000×g for 30 min at 4°C. 
T7 RNA polymerase was further purified by anion exchange chromatography. 
Q-Sepharose column (around 20 ml of resin) was equilibrated with T7 buffer. The supernatant 
was loaded with a flow rate of 1 ml/min. The polymerase was eluted by salt gradient from 
50 mM NaCl to 500 mM NaCl in 300 ml in T7 buffer at a flow rate 3 ml/min. Fractions were 
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analyzed by SDS-PAGE gel electrophoresis. Fractions containing polymerase were further 
dialyzed against 100 volumes excess of buffer: 10 mM Tris, 1 mM EDTA, 10 mM NaCl, 
1 mM DTT, pH 8.0. T7 RNA polymerase was stored in the same buffer with addition of 
50% Glycerol at -20°C. 
 
2.2.2.3. Pipetting scheme for “analytical” and “preparative” scale CF 
The pipetting scheme was prepared for each experiment according to Table 2.3. All 
stock solutions were prepared as described previously [161]. For Mg2+ optimization screens 
the scheme from Table 2.4 was used.  
 
  Concentration Analytical scale Preparative scale 
Compound Stock Final MM (µl) FM (µl) RM (µl) MM (µl) FM (µl) RM (µl) 
NaN3 (%) 10 0.05 32 
  
90 
  PEG8000 (%) 40 2 323 
  
900 
  KOAc (mM) 4000 150.8 243 
  
679 
  Mg(Oac)2 (mM) 1000 7.1 46 
  
182 
  HEPES buffer (M) 2.5 0.1 237 
  
660 
  Complete (×) 50 1 129 
  
360 
  Folinic acid (mg/ml) 10 0.1 65 
  
180 
  DTT (mM) 500 2 26 
  
72 
  NTP mix (×) 75 1 86 
  
240 
  PEP (mM) 1000 20 129 
  
360 
  AcP (mM) 1000 20 129 
  
360 
  Amino-acid mix (mM) 4 0.5 806 750 
 
2250 2125 
 RCDWMDE (mM) 16.7 1 386 
  
1078 
  Detergent (%) 10 1 - 
  
1800 
  
   
Σ 2637 
  
Σ 9211 
  Mastermix       2452 184   8699 512 
S30 buffer (%) 100 35   2100     5950   
Pyruvat kinase (mg/ml) 10 0.04     2     4 
TRNA (mg/ml) 40 0.5 
  
6 
  
12 
T7RNAP (U/ml) 420 6 
  
6 
  
14 
RNasin (U/ml) 40 0.3 
  
4 
  
9 
DNA (µg/ml) 200 0.015 
  
34 
  
75 
S30 extract (%) 100 35 
  
158 
  
350 
Distilled water             226 24 
Total     2637 5302 394 9211 17000 1000 
Table 2.3. General pipetting protocol for CECF reactions. 
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Number of reaction 1 2 3 4 5 6 
Final Mg2+ concentration (mM) 12 13 14 15 16 17 
Preparation of FM 
      µl of FM 883.7 883.7 883.7 883.7 883.7 883.7 
µl of 100 mM Mg(OAc)2 0 10 20 30 40 50 
µl of water 116.3 106.3 96.3 86.3 76.3 66.3 
Preparation of RM 
      µl of RM 65.7 65.7 65.7 65.7 65.7 65.7 
µl of 100 mM Mg(OAc)2 0 0.75 1.5 2.25 3 3.75 
µl of water 9.3 8.55 7.8 7.05 6.3 5.55 
Table 2.4. Example of Mg2+ optimization screen. 
2.2.2.4. Reaction setup 
“Analytical scale” reactions were carried out in containers showed on Figure 2.2a at 
32°C overnight with gentle shaking (120 rpm) with dialysis membrane cut-off 14 kDa. For 
“preparative scale” reactions slide-A-lyzer setup (with the same membrane cut-off) was used 
(Figure 2.2b) and the mixture was incubated at 32°C overnight. 
 
Figure 2.2. Design of CECF expression reaction containers. (a): Plexiglas reaction chamber for “analytical 
scale” reactions, and (b): slide-A-lyzer setup for “preparative scale” reactions. RM compartments are separated 
from FM compartments by dialysis membranes. Filling openings for RM and FM are sealed by appropriate lids 
and parafilm to prevent evaporation. 
2.2.3. E.coli culture and Cx32 overexpression 
Preliminary E.coli overexpression was done following standard expression protocol in 
LB broth. Briefly, 6 L of LB medium with 100 mg/l ampicillin was inoculated with a fresh 
overnight LB culture of appropriate bacteria strain with plasmid encoding Cx32 at starting 
OD600 around 0.2. Bacteria were cultured in 2 L flasks (500 ml of media per 1 flask) at 37°C 
with vigorous shaking (120 rpm) until OD600 of 0.6-0.8 was obtained. Then, connexin 
expression was induced with IPTG of 1 mM final concentration and bacteria were further 
incubated at 37°C for 5 h. The cells were harvested by centrifugation at 5000×g for 30 min at 
4°C. After that they were either resuspended in appropriate buffer for further total membrane 
isolation or frozen in liquid nitrogen and stored at -80°C. 
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In next experiments auto-induction media (AIM) was used for connexin expression 
[163]. One colony of freshly transformed bacteria was grown overnight at 37°C in 20 ml of 
LB broth with 1% glucose and appropriate antibiotic in 100 ml flask. Next morning 0,5 L of 
AIM without 5052 but with 1% glucose and antibiotic was inoculated with this overnight 
culture and was grown at 37°C for approximately 5 h in 2 L flask. 6 L of AIM with 
appropriate antibiotic were inoculated with starting OD600 around 0.2. The bacteria were 
cultured in 2 L flasks at 37°C with vigorous shaking (120 rpm). Glucose level in media was 
controlled by commercial glucose tests (Merckoquant®). When glucose was depleted, culture 
was either cooled to 20°C for overnight incubation or left at 37°C for 5-7 h. The cells were 
harvested by centrifugation at 5000×g for 30 min at 4°C and then either immediately 
resuspended for further protein purification or frozen in liquid nitrogen and stored at -80°C. 
For “analytical scale” expression same procedure was used. Briefly, single colony was 
cultured in 20 ml of AIM with antibiotic at 37°C overnight. Next morning the cells were 
pelleted down by centrifugation, resuspended in appropriate buffer and further used for 
expression level analysis. 
For 1 L of AIM were mixed 930 ml of ZY broth (1% Trypton, 0.5% Yeast extract), 
2 ml of 1 M MgSO4 stock, 20 ml of 50×5052 stock (25% glycerol, 2.5% glucose, 10% α-
lactose), 50 ml of 20×NPS stock (0.5 M (NH4)2SO4, 1 M KH2PO4, 1 M Na2HPO4). ZY broth 
and NPS stock were autoclaved; MgSO4 and 5052 stocks were sterile filtered. 
 
2.2.4. Biochemical methods 
2.2.4.1. Gel electrophoresis – denaturing SDS-PAGE 
The separation of denaturated proteins with sodium dodecyl sulfate (SDS) was 
performed using linear gradient gels. These gels have two considerable advantages over 
uniform concentration gels: they fractionate proteins over a wider range of molecular weights 
than any uniform concentration gel; the gradient in pore size causes significant sharpening of 
protein bands during migration [164]. The solutions used for gel preparation are given in 
Table 2.5. 
The separation gel was casted by mixing “heavy” and “light” gels using the gradient 
mixer (Bio-Rad, Germany) as described previously [164]. A thin layer of isopropanol was 
overlaid, to fasten the polymerization by avoiding contact with oxygen. The separation gel 
polymerized overnight in the electrophoresis apparatus. Next morning after rinsing with 
deionized water, the stacking gel was poured and polymerized for 3 h. 
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Compound 16.2% “heavy” gel, ml 7.8% “light” gel, ml 4% stacking gel, ml 
Sucrose 6 g - - 
AA/BAA* 30%/0.8% 16 6.5 3 
Water 4 15 14.5 
3 M Tris pH 8.8 3.125 3,125  - 
1 M Tris pH 6.8 - - 2.5 
SDS 10% 0.250 0.250 0.200 
Total 26 25 20 
TEMED 100% 4 µl 8 µl 20 µl 
APS 20% 8 µl 16 µl 40 µl 
 
Table 2.5. Resolving gel mixture for gradient gels.  
* mixture of 30% Acrylamide and 0.8% Bisacrylamide 
For protein samples preparation the loading buffer was added (25 mM Tris-HCl 50% 
Glycerol, 500 mM DTT, 10% SDS, 0.1% bromophenol blue, pH 6.8) in sample:buffer ration 
5:1. Mixture was incubated for 15 min at room temperature and loaded onto acrylamide gel. 
The separation was carried out by applying an external voltage of 150 V for 1.5 h. 
Anode and cathode buffer: 25 mM Tris-base, 200 mM Glycine, 0.1% SDS. 
 
2.2.4.2. TCA protein precipitation 
Protein precipitation by TCA is widely used to concentrate samples for gel analysis in 
a polyacrylamide gel and to remove detergents, which can have negative influence on 
protein’s migration in the SDS PAGE [165]. Brief procedure: to the protein sample 100% 
trichloroacetic acid (TCA) was added in ratio 1:10 (protein solution:TCA), to get a 10% final 
concentration. The mixture was incubated for 15 min at –20ºC or 30 min on ice. Then the 
sample was centrifuged for 15 min at 16000×g and 4ºC. The supernatant was carefully 
discarded; the pellet was retained and resuspended in 50-100 µl 0.1 M NaOH. The gel-
loading buffer was added (as described before) and sample was further analyzed by 
acrylamide gel. 
 
2.2.4.3. Staining of proteins on gels 
The protein bands were visualized by staining the gel with Coomassie Brilliant Blue 
staining solution (0.12% Coomassie Brilliant Blue G250, 10% H3PO4, 10% (NH4)2SO4, 
20% methanol) for 2 h. For destaining 3% acetic acid solution was used. 
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2.2.4.4. Western-Blot analysis 
Proteins were transferred from gel onto PVDF membrane (Macherey-Nagel, Dueren, 
Germany) in the blotting tank apparatus (Bio-Rad, Germany) for 1h at 100 V. The transfer 
buffer (48 mM Tris-base, 38.6 mM Glycine, 0.04% SDS, 20% Methanol) was used to pretreat 
the membrane, the gel and the filter paper. After transfer, the membrane was briefly rinsed 
with TBST buffer (20 mM Tris-HCl, 100 mM NaCl, 5% Glycerol, 0.05% Tween20, 0.02% 
NaN3, pH 8.0), and afterwards incubated in TBST-milk buffer (20 mM Tris-HCl, 100 mM 
NaCl, 5% Glycerol, 0.05% Tween20, 0.02% NaN3, 5% dry milk, pH 8.0) overnight. Next 
morning it was incubated for 1.5 h with the primary antibodies (connexin 32 mouse 
monoclonal lgG1, Santa Cruz, Dallas, USA), diluted (1:2000) in 8 ml TBST-milk buffer. 
After two 5 min washes with the same buffer the membrane was incubated with the secondary 
antibodies (goat anti-mouse lgG-AP, Santa Cruz, Dallas, USA) again in 8 ml TBST-milk 
buffer (with 1:2000 dilution). Finally, the membrane was washed two times with TBST 
buffer. Substrate NBT/BCIP solution (Thermo, USA) was used to elicit the signal by 
chemiluminescence, yielding an intense, insoluble black-purple precipitate when reacted with 
alkaline phosphatases. 
 
2.2.5. Protein purification 
2.2.5.1. Isolation of E.coli total membranes 
Cell pellets were resuspended in ice-cold homogenization buffer (20 mM Tris-HCl, 
500 mM NaCl, 1 mM EDTA, 1 mM EGTA, pH 7.5) in ratio 1:5 (1 g of cells per 5 ml of 
buffer). Deoxyribonuclease I from bovine pancreas (Sigma-Aldrich, Germany) was added to 
remove DNA from the cell suspension after lysis (5 mg of DNAse per 30 g of cells). The cells 
were disrupted by passing through the microfluidizer (M110-P, Microfluidics, Newton, USA) 
precooled at 4°C with three passes. The suspension was loaded onto glycerol gradient 30-
100% and centrifuged for 3 h at 4°C in the swinging bucket rotor (SW-32Ti, Beckmann, 
USA). For gradient preparation glycerol dilutions (0.5 ml 100%, 0.5 ml 90%, 1 ml 80%, 1 ml 
60%, 5 ml 30%) in homogenization buffer starting from the heaviest were pipetted into thick 
walled centrifugation tubes. After each dilution tubes were placed at -80°C for 10 min until 
the layer is either very viscous or frozen. With this procedure a very sharp gradient was 
created. On top of the last frozen layer 20 ml of the sample was pipetted.  
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After centrifugation fractions containing 60-100% glycerol were collected and 
dialyzed (dialysis membrane cut-off 14 kDa) against 1 l of ice-cold homogenization buffer 
overnight. 
Next morning the dialysis was terminated, 1% of Triton X100 was added to the 
suspension in order to wash the membranes. The mixture was incubated for 1 h at 4°C under 
gentle rotation. Then the membranes were sedimented by centrifugation at 120000×g for 1 h 
at 4°C. The supernatant was discarded; the pellet was resuspended in 150 ml of ice-cold 
solubilization buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.5). 
 
2.2.5.2. Protein solubilization 
  For solubilization screening the suspension of crude total membranes in solubilization 
buffer was incubated overnight at 4°C under gentle rotation within 1% of different detergents 
(DM, DDM, OG, FOS10, FOS12, FOS14, Brij35, NLS). Then the suspension was 
centrifuged at 120000×g for 1 h at 4°C to remove insoluble material. The pellets and 
supernatants were further analyzed by SDS PAGE gel electrophoresis. 
 For “preparative scale” purification combination of DM and NLS was used. First 1% 
of DM was added to the membrane suspension. The mixture was incubated at 4°C for 1 h 
with moderate stirring. Next 1% of NLS was added and the suspension was further incubated 
on stirrer overnight. Insoluble proteins and lipids were removed by centrifugation with the 
same parameters. The supernatant was further used for connexin 32 purification. 
In later experiments solubilization of Cx32 was carried out by adding 2% of NLS to 
the membrane suspension. The rest of the procedure was unchanged. 
 
2.2.5.3. Affinity chromatography 
Ni2+-NTA beads (Qiagen, Germany) were first washed with 5 column volumes (CV) 
of deionized water and then pre-equilibrated with the same volume of solubilization buffer 
containing 1×CMC of different detergents.  
In case of “analytical scale” purification binding of the solubilized material was done 
using gravity flow columns. 600 µl of the supernatant after the last centrifugation was loaded 
onto 200 µl of prepared Ni2+-NTA beads. After washing the resin with 1 ml of equilibration 
buffer bound proteins were eluted with 600 µl of elution buffer (20 mM Tris-HCl, 100 mM 
NaCl, 50 mM EDTA, 1×CMC of different detergents). All manipulations were done at room 
temperature. 
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Given “preparative scale” purification the supernatant containing solubilized proteins 
was first diluted with solubilization buffer to reduce NLS concentration to 0.5% and then 
incubated with pre-equilibrated Ni2+-NTA beads (with solubilization buffer containing 
0.5% NLS) at 4°C for 5 h under gentle rotation. Usually for 1 g of initial bacterial cells 0.2 g 
of dry Ni2+-NTA resin was taken. Then resin was loaded onto chromatographic column (GE 
Healthcare, USA) and further washed with 5×CV of washing buffer (20 mM Tris-HCl, 100 
mM NaCl, 30 mM Imidazole, 0.5% NLS, pH 7.5) using AKTA purifier chromatographic 
system (GE Healthcare, USA). Next washing step was carried out to exchange NLS to less 
“harsh” detergent. For this purpose the column was washed additionally with 5×CV of 
washing buffer, containing 0.2% DDM or 0.2% SDS. Finally, bound proteins were eluted in 
2×CV of elution buffer (20 mM Tris-HCl, 100 mM NaCl, 400 mM Imidazole, pH 7.5) with 
appropriate detergent. If SDS was used in washing and elution buffer the purification on 
chromatographic system was done at room temperature, in other case – at 4°C. 
Different chromatography parameters were checked for optimization of the 
purification: the beads volume, the concentration of detergents, the concentration of 
imidazole at washing stage and the effect of urea. All these trials were done using the 
“analytical scale” purification protocol. 
 
2.2.5.4. Anion-exchange chromatography 
MonoSTM and MonoQTM ion-exchange columns (GE Healthcare, USA) were used to 
separate connexin 32 with cleaved and not MstX in case of in vivo cleavage with TEV 
protease. 
Due to high cationic strength of MonoSTM resin, the eluate from Ni2+-NTA in 
0.2% Brij35 was dialyzed (membrane cut-off 14 kDa) overnight against 100-fold excess of 
column equilibration buffer (20 mM Tris-HCl, 0.2% Brij35, pH 6.0) at 4°C. Next morning 
dialysis was terminated and the protein solution was centrifuged at 20000×g for 20 min at 4°C 
to remove aggregates. The clear supernatant was loaded with a flow rate of 0.1 ml/min onto 
pre-equilibrated with 5×CV of equilibration buffer MonoSTM column. Protein was eluted by 
salt gradient (in equilibration buffer) up to 1 M NaCl in 20×CV at the same flow rate. 
Fractions were collected and further analyzed by SDS-PAGE and Western-blot. 
In case of MonoQTM column the same protocol was used with deviations only in the 
equilibration buffer (20 mM Tris-HCl, 0.2% Brij35, pH 8.0). 
In several experiments 6 M Urea was added to the equilibration buffers to improve the 
separation.  
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2.2.5.5. Size-exclusion chromatography (gel-filtration) 
To control hemichannel formation size-exclusion chromatography was used. Eluates 
from metal-affinity chromatography were dialyzed (membrane cut-off 14 kDa) overnight 
against 100-fold excess of elution buffer without imidazole (20 mM Tris, 100 mM NaCl, 
0.2% DDM or 0.1% SDS, pH 7.5). Next, the proteins suspension was concentrated using 
centrifugal filter (Millipore, USA) with membrane cut-off 30 kDa to 0.5 ml. Aggregates were 
removed by centrifugation at 20000×g for 20 min. Supernatant was either loaded onto 
Superose® 6HR 24 ml column (GE Healthcare) pre-equilibrated with 30 ml of suitable buffer 
(20 mM Tris-HCl, 100 mM NaCl and 5×CMC of appropriate detergent, pH 7.5) or used for 
refolding experiments and only then analyzed by gel-filtration. The column flow rate was 
adjusted to 0.1 ml/min. The fractions corresponding to peeks on the chromatogram were 
pooled and further analyzed by SDS-PAGE gel electrophoresis. The column calibration 
curves are shown on Figure 2.3. 
 
Figure 2.3. Calibration curves for Superose6HR 24 ml column. Globular proteins were used as standards.  
2.2.6. Refolding of denatured protein 
2.2.6.1. Refolding by dialysis 
Amphipol (A8-35) mediated refolding of Cx32 solubilized in SDS was carried out as 
described previously [166]. Briefly, to Cx32 after elution from Ni2+-NTA column and dialysis 
against buffer without imidazole but with 0.1% SDS amphipol was added at the ratio 10 g of 
A8-35 per 1 g of SDS-unfolded connexin. The mixture was incubated for 30 minutes at room 
temperature and then was loaded into slide-A-lyzer (with membrane cut-off 20 kDa) and 
dialyzed against 100-fold excess of refolding buffer (20 mM Tris-HCl, 100 mM NaCl, 
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1 mM KCl, pH 7.5) at 4°C overnight.  Aggregates and precipitated SDS were removed by 
centrifugation at 20000×g for 20 min at 4°C. Further this mixture was concentrated and 
analyzed by size-exclusion chromatography. 
 
2.2.6.2. SDS precipitation by KCl 
In this case refolding of Cx32 form SDS to amphipol was done by stepwise addition 
of 1 M KCl stock solution to protein suspension. The same procedure as described above was 
used. Only instead of dialysis after short incubation at room temperature sample was moved 
on ice and KCl was added by small portions to final concentration equal 100 mM. 
Precipitated SDS as its potassium salt was removed by centrifugation at 20000×g for 20 min 
at 4°C. 
 
2.2.7. Characterization 
2.2.7.1. MALDI-TOF analysis 
For mass spectrometric analysis of Cx32 by MALDI-TOF pure protein solution in 
DDM obtained by size-exclusion chromatography was used. Measurements were carried out 
at the mass spectrometry analysis service of Institute of Structural Biology, Grenoble, France.  
 
2.2.7.2. Dynamic light scattering to study samples monodispersity 
The measurements were carried out using Dyna Pro-E-20-660 devise (Proterion corp., 
USA) in quartz cuvettes with 57 µl volume (Helma, z=8.5 mm, path length=3 mm). 
 
2.2.7.3. Electron microscopy analysis of solubilized and reconstituted into liposomes 
Cx32 
Samples of Cx32 in different detergents or reconstituted into liposomes were adsorbed 
to the clean side of a carbon film formed on mica (the carbon-mica interface) and negatively 
stained using 1% uranyl acetate. Photographs were taken under low-dose conditions with a 
JEOL 1200 EXII electron microscope operating at 100 kV at a nominal magnification of 
40000×.	 All measurements were carried out in the electron microscopy laboratory of 
Institute of Structural Biology, Grenoble, France.  
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2.2.8. Crystallization of Cx32 in meso 
Fractions corresponding by size to hemichannel after size-exclusion chromatography 
of Cx32 refolded into amphipol were concentrated to final protein concentration 20-30 mg/ml 
using centrifugal filter with membrane cut-off 30 kDa. Protein concentration was controlled 
by NanoDrop spectrophotometer (Thermo, USA). 
Detergents (OG, DDM, FOS12) were added to the concentrated protein solution till the 
aimed concentration is achieved. Detergent concentration was checked by IR spectroscopy. 
The protein solution was added to monooleoyl in a ratio 1:1 (vol:vol) and several passes 
through interconnected syringes for cubic phase preparation were performed. Cubic phase 
was ready for usage after 1-2 days. 
Crystallization was carried out using robot for in meso membrane protein crystallization 
(NT 8 Crystallography, Formulatrix, USA). Crystallization probes were visualized and 
systematically scanned by automated system for imaging crystallization probes (Rock Imager 
1000, Formulatrix, USA). All crystallization experiments were done in the membrane protein 
crystallization platform of Institute of Structural Biology, Grenoble, France. 
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3. Results and discussion 
3.1. Expression and purification of human connexin 32 in E.coli using 
membrane-targeting expression tag (MstX from Bacillus subtilis) 
For structural studies of integral membrane proteins (IMPs) the production of large 
amounts of properly folded protein plays crucial role. Highly hydrophobic membrane proteins 
require auxiliary proteins to prevent their aggregation during the protein folding process. It is 
thus likely that production of eukaryotic IMPs in bacteria is additionally limited due to the 
complexity involved in the biogenesis of IMPs, coordinated by the ribosome and the SecYEG 
translocon assisted by chaperones such as SecB and the ATPase motor SecA, some of which 
may be needed to be co-overexpressed and/or impose additional specificity [167]. 
Mistic is a membrane-associated protein originally discovered in Bacillus subtilis. It 
was shown to enhance expression levels of a large number of foreign IMPs at the membrane 
of E.coli, when used as a fusion partner linked to the N-termini of cargo proteins [168–171]. 
It was showed that Mistic lacks identified signal sequence: no any LSS was identified. Also 
its overexpression, whether alone or in fusion to other IMPs, apparently prevents the toxicity 
issues associated with overloading the protein translation machinery [168].  
Taking into account previous unsuccessful attempts to overexpress full-length 
connexins incorporated into cell membranes in E.coli using water-soluble fusion partners 
(thioredoxin [17] and glutathione S-transferase [13]) we decided to fuse Mistic to N-terminus 
of our target human connexin 32 to enhance membrane-targeted overexpression. Construction 
without any fusion tag was also generated and used as control of expression yield.  
 
3.1.1. Assembling and expression of human connexin 32 gene in fusion with Mistic and 
enterokinase cleavage site in between 
3.1.1.1. Cloning strategy 
Human Cx32 gene was amplified from pMA_Cx32 plasmid (kindly provided by 
Dr. Carsten Zeilinger) by PCR using two primers - frwBamHEKCx32 and revXhoIhCx32. 
PCR product was digested with BamHI and XhoI DNA restriction enzymes and cloned into 
pSCodon1.2 vector containing already MstX gene followed by enterokinase (EK) cleavage 
site (the vector has been produced earlier by Taras Balandin in our laboratory). Final 
construct is illustrated on Figure 3.1 and have molecular weight 45.9 kDa. This construct was 
designated as H6MstXEKhCx32. Nucleic acid and amino acid sequences of human Cx32 and 
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Mistic can be found in appendix. E.coli strains (SE1, C43, Lemo21) were transformed with 
the plasmid and used for expression.  
 
Figure 3.1. Basic features of the generated construct of human connexin 32 gene in fusion with MstX and 
enterokinase cleavage site in between. 
3.1.1.2. Expression and purification 
Test expression in SE1 E.coli strain in auto induction media (AIM) 
One colony of freshly transformed bacteria (SE1 strain) with a new plasmid construct 
was cultured for 16 h at 37°C in 25 ml of AIM with 100 mg/L ampicillin. As expression rate 
control empty pSCodon1.2 vector was used. It was also transformed into SE1 cells. 
Next morning OD600 was measured. Normalized volumes of two cultures 
(2 OD600×ml) were transferred to tubes and cells were pelleted down by centrifugation. Each 
pellet was resuspended in 200 µl of 1× gel-loading buffer and analyzed by SDS-PAGE and 
Western-blot. Results are illustrated on Figure 3.2. This indicates that new construct of Cx32 
is successfully overexpressed and different oligomeric states are observed. Oligomerization 
may be caused not only by connexin 32, but also MstX have strong tendency to form dimers 
and trimmers [172]. 
 
Figure 3.2. Western-blot of total lysates of cells with 
new Cx32 construct and with empty pSCodon1.2 
vector using Anti-Connexin32 mouse antibody, anti-
mouse lgG alkaline phosphatase conjugate and 
BCIP/NBT enzyme substrate. 5 µl, 10 µl, and 20 µl of 
samples were loaded. M: size marker. Different bands 
correspond to different oligomeric states of expressed 
H6MstXEKhCx32. With arrow monomer band is 
indicated. 
Monomer band, depicted on this picture with arrow, migrate in the gel slightly faster 
than it should. Such behavior was previously reported for connexins and may indicate that 
SDS in loading buffer does not fully unfold connexins. Moreover, variety of bands on 
immunoblot cannot be explained only by oligomerization. This leads to conclusion that 
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connexins are associated with other proteins in E.coli and migrate together in acrylamide gel. 
Transfer efficiency and primary antibody binding of different oligomers varies significantly 
which makes total Cx32 yield calculations very complicated. For this further protein 
purification is essential. 
Same procedure was used to examine protein expression rate over time. Each hour 
culture OD600 and glucose concentration were measured. From normalized volumes of cell 
suspension samples for SDS-PAGE were prepared. Resulting Western-blot is shown on 
Figure 3.3. This picture illustrates that induction with lactose successively starts after bacteria 
have consumed all the primary hydrocarbons. It also shows that 16 hours incubation period is 
sufficient for cells to produce significant amount of Cx32. Longer incubation period leads to 
proteolysis (data not shown). 
 
Figure 3.3. Western-blot analysis of total lysates of 
cells with Cx32 construct collected on different time 
starting from inoculation. M: size marker. Moment 
when zero glucose concentration has been observed is 
depicted with arrow. 
Choice of best suitable E.coli strain for overexpression 
To find optimal E.coli strain for our construct expression we compared protein yields 
in three strains – C43, Lemo21 and SE1. C43 and Lemo21 were proposed suitable for toxic 
proteins or/and membrane proteins overexpression while SE1 possess toxin/antidote system 
which leads to better plasmid stabilization. 
pSCodon1.2 containing H6MstXEKhCx32 was transformed into these three strains. 
Expression was carried out in AIM with 100 mg/l ampicillin for 16 h at 37°C. Total cell 
lysates were loaded onto glycerol gradients 30-100% and fractionated after centrifugation. 
Fractions corresponding to 80-100% glycerol were diluted to reduce glycerol concentration to 
5% and applied to glycerol gradients second time. Centrifugal tubes after both centrifugations 
are illustrated on Figure 3.4. This picture indicates that in case of SE1 strain membrane 
fraction is larger, which may lead to better protein yield. 
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Figure 3.4. Photograph of centrifugal tubes with glycerol gradients after first (A) and second (B) centrifugations. 
After first centrifugation fractions corresponding to 80-100% glycerol were diluted to final glycerol 
concentration 5% and loaded onto gradient second time.  
To examine this speculation we checked all fractions with SDS-PAGE and Western-
blotting Figure 3.5. This analysis confirmed that in case of SE1 strain Cx32 yield was greater 
and more protein was incorporated into cell membranes or expressed as inclusion bodies in 
comparison with other two strains. 
 
Figure 3.5. Western-blot analysis of fractions with different glycerol concentrations after two centrifugations for 
three E.coli strains – SE1, Lemo21 and C43. M: size marker. L: total lysate. Numbers correspond to glycerol 
concentrations: 1 – 5%, 2 – 30%, 3 – 40%, 4 – 60%, 5 – 80%, and 6 – 100%.  
Detergents screen for Cx32 solubilization 
To study the solubility of the expressed Cx32 in different detergents and to choose the 
best suitable one for further purification we performed solubilization screen in 7 detergents – 
Fos10, Fos12, Fos14, DM, DDM, OG, Brij35. Membranes in fraction with 80-100% glycerol 
after second centrifugation were used. First they were dialyzed overnight at 4°C to remove 
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glycerol and then mixed with detergents to final detergent concentrations 1%. This mixture 
was kept overnight at 4°C on magnetic stirrer. Next morning samples were centrifuged and 
analyzed. Results are shown on Figure 3.6. Fos-cholines were more efficient and less Cx32 
was observed in pellets when they were used for solubilization. Inside this family of 
detergents other tendency may be indicated – longer detergent hydrophobic tail helps to 
increase solubilization rate. 
 
Figure 3.6. Western-blot analysis of different detergents efficiency for Cx32 solubilization. M: size marker; l: 
mixture of membranes with detergent before centrifugation; s: supernatant after centrifugation; p: pellet 
resuspended in corresponding volume of 1× gel-loading buffer; t: membranes suspension before addition of 
detergent.  
Purification of solubilized in different detergents Cx32 using Ni2+-NTA agarose 
Supernatants after solubilization test were further purified using Ni2+-NTA agarose 
and following “analytical scale” purification protocol. Resulting eluates were analyzed by 
SDS-PAGE and Western-blot (Figure 3.7). Same experiment was carried out with various 
urea concentrations  (0.5-6 M) and various pH of solubilization buffer (pH 7-9). In all cases 
similar results were observed – only small amount of solubilized protein was found in eluates, 
around 90% of Cx32 flow through Ni2+-NTA agarose; more “harsh” detergents like fos-
cholines give better result in terms of Cx32 yield in eluates. We assume that such detergents 
favor better exposition of polyhistidine-tag, which results into better binding to the affinity 
resin. Nevertheless, total yield of purified protein was quite high (around 0.5 mg per 1 L of 
culture, determined from SDS-PAGE using a BSA band with known protein amount as a 
reference). So we decided to continue experiments with this construct and to proceed with 
cleaving-off MstX from Cx32. 
For further enterokinase cleavage analysis the purification of Cx32 without urea was 
upscaled. Purification buffer with pH 8.0 was used. 
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Figure 3.7. Immunoblot analysis of 
different fractions of Cx32 solubilized in 
several detergents and purified using Ni2+-
NTA agarose (all without urea). M: size 
marker; bc: Cx32 solution in detergent 
before purification; ft: flow through; el: 
eluate. 
3.1.1.3. Mistic cleavage tests with enterokinase  
First, eluates after affinity chromatography were dialyzed overnight against 100-fold 
excess of EK cleavage buffer (20 mM Tris-HCl, 50 mM NaCl, 2 mM CaCl2, pH 8.0 with 
corresponding detergents – DM, FOS12 or Brij35). Cx32 concentrations in eluates were 
determined from SDS-PAGE using a BSA band with known protein amount as a reference. 
Next, samples were diluted with same buffers to final Cx32 concentration 0.2 mg/ml. 20 µl 
aliquots were mixed with different amounts of enterokinase (final EK concentration 0.1 µg/ml 
and less) and incubated overnight at 20°C or 4°C. These samples were analyzed further by 
Western-blotting. Figure 3.8 shows resulting immunoblot in case of DM (0.2%). No desired 
cleavage pattern is observed, either EK concentration was to low and no cleavage occurred 
(rows 3-4) or unspecific proteolysis was observed (rows 1-2). More detailed screening of EK 
concentration gave the same results. Similar picture was observed for Cx32 purified in Brij35, 
while in case of Fos12 we did not see any cleavage at all.  
 
Figure 3.8. Western-blot analysis of Cx32 
(solubilized and purified in DM) samples with 
different enterokinase concentrations 
incubated overnight at 20°C and 4°C. M: size 
marker; l: 0.1 µg/ml EK; 2: 6 ng/ml EK; 
3: 0.4 ng/ml EK; 4: 0.02 ng/ml EK; c: control 
samples without EK; c*: Cx32 sample before 
incubation.  Bands indicating unspecific 
proteolysis are depicted with arrows. 
It was previously reported that detergents have strong influence on proteases activity 
[173] and in case of “harsh”  detergents it decreases dramatically. This explains our 
observations in case of Fos12. Results for DM and Brij35 indicate that enterokinase cleavage 
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site is not exposed well enough for efficient EK binding, which prevents MstX cutting-off 
under low EK concentrations. Construction with longer linker between Mistic and Cx32 was 
generated and examined for this reason (data not shown). Unfortunately we obtained the same 
results – either no cleavage was observed under low EK concentrations, or unspecific 
proteolysis occurred. That is why we decided to replace EK cleavage site with thrombin 
cleavage site and to try luck with a new construction. 
 
3.1.2. Assembling and expression of human connexin 32 gene in fusion with Mistic and 
thrombin cleavage site in between 
3.1.2.1. Cloning strategy 
Cx32 gene was amplified from pSCodon1.2_H6MstXEKCx32 plasmid by PCR using 
two primers - frwBamHTrhCx32 and revXhoIhCx32. PCR product was digested with BamHI 
and XhoI DNA restriction enzymes and cloned into pSCodon1.2 vector containing already 
MstX gene. Final construct is illustrated on Figure 3.9 and has a calculated molecular weight 
of 45.7 kDa. This construct was designated as H6MstXTrhCx32.  
 
Figure 3.9. Basic features of the gererated construct of human connexin 32 gene in fusion with MstX and 
thrombin cleavage site in between. 
3.1.2.2. Expression and purification 
Expression and puriffication were carried out using standart protocol described in 
methods. We repeated solubilization sceening using several detergents (Fos12, Fos14, DM, 
DDM, OG, MTAB, Brij35). Results for two of them (MTAB and Fos12) are shown on 
Figure 3.10. 
Replacing protease cleavage site had no significant influence on purification process 
and final Cx32 yield.  Still more “harsh” Fos12 gave better results and almost twice more 
protein could be eluted from Ni2+-NTA column when it is used for solubilization (comparing 
to “mild” DDM or MTAB detergents). Again, total Cx32 yield was around 0,5 mg per 1 L of 
culture. 
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Figure 3.10. Western-blot analysis of MTAB and Fos12 efficiency for Cx32 solubilization and purification 
using Ni2+-NTA agarose. M: size marker; p: pellet after solubilization and centrifugation; s: supernatant after 
solubilization and centrifugation; ft: flow through column pre-packed with Ni2+-NTA resin; el: eluate from Ni2+-
NTA column; 1: fraction with less then 30% of glycerol after E.coli total membrane sedimentation; 2: fraction 
with more then 30% of glycerol; lys: total cells lysate.  
Low efficiency of widely used for membrane proteins solubilization “mild” non-ionic 
detergents (like DM, DDM, or OG) brought as to idea that maybe our Cx32 in fusion with 
Mistic is overexpressed as inclusion bodies. In this case commonly used approach is to reduce 
expression rate so that all synthesized target protein have enough time to incorporate into 
cellular membranes. For this we tried expression at low temperatures starting from 18°C. 
Cultivation period was increased so that after bacteria had consumed all the primary 
hydrocarbons (glucose concentration was controlled over time) induction took not less than 6 
h. In this case total Cx32 yield reduced dramatically and only around 0.1 mg of target protein 
per 1 L of culture could be purified. Nevertheless, we observed the same Cx32 behavior – 
usage of Fos12 allowed us to solubilize around 80% of target protein from E.coli total 
membranes, while using more “soft” detergents we managed to extract only 20% of Cx32. 
That is why we returned to standard 37°C expression and purification protocol, 
upscaled it and purified our new H6MstXEKCx32 construct in three detergents – Fos12, DM 
and Brij35. Further this protein was used for screening of thrombin cleavage conditions. 
 
3.1.2.3. Mistic cleavage tests with thrombin  
First, eluates after affinity chromatography were dialyzed overnight against 100-fold 
excess of thrombin cleavage buffer (200 mM Tris-HCl, 1 M NaCl, 25 mM CaCl2, pH 8.0 with 
0.2% of DM, FOS12 or Brij35) at 4°C. Cx32 concentrations in eluates were determined from 
SDS-PAGE using band with known BSA concentration as a reference. Next, samples were 
diluted with same buffers to final Cx32 concentration 0.2 mg/ml. 20 µl aliquots were mixed 
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with different amounts of thrombin (final thrombin concentration 40 U/ml and less) and 
incubated overnight at 20°C. Further this samples were analyzed by immunoblotting (Figure 
3.11). 
Unlike enterokinase thrombin don’t lose its activity in the presence of “harsh” Fos12. 
This means that higher amounts of target Cx32 can be purified and subjected to Mistic 
cleavage. But still results were disappointing. Even 1000-fold excess of thrombin amount 
above recommended by supplier was not enough to cut-off Mistic from all connexin in 
sample. Unspecific proteolysis again occurred, although its results were not directly 
visualized by immunoblotting. This we understood comparing integral intensities of bands 
corresponding to monomer and dimer in the samples with and without thrombin. Summarized 
integral intensity of all bands in the samples with thrombin (for example, column “1” with 
DM on the immunoblot) was twice lower than in the control sample (column “c” with DM). 
More detailed screening of cleavage conditions (protease concentration, temperature, pH of 
used buffer) gave no significant improvement – higher concentrations of thrombin in the 
reaction mixtures caused degradation of all connexin 32, while with smaller one not all target 
protein was cut.  
 
Figure 3.11. Immunoblot analysis of Cx32 
samples with different thrombin 
concentrations incubated overnight at 20°C. 
M: size marker; l: 40 U/ml of thrombin; 
2: 8 U/ml; 3: 1.6 U/ml; 4: 0.3 U/ml; c: control 
samples without addition of thrombin; Bands 
indicating unspecific proteolysis are depicted 
with arrows. Anti-Connexin32 mouse 
antibody, anti-mouse lgG alkaline 
phosphatase conjugate and BCIP/NBT 
enzyme substrate were used.  
Further work on this direction seemed unreasonable and we decided to proceed using 
other protease to remove Mistic, FXa protease. Also, taking into account low binding rate of 
target protein to Ni2+-NTA resin when polyhistidine-tag was placed before Mistic, we decided 
to move it to C-terminus of Cx32. The results are illustrated in the next section. 
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3.1.3. Assembling and expression of human connexin 32 gene in fusion with Mistic and 
factor Xa protease cleavage site in between 
3.1.3.1. Cloning strategy 
Cx32 gene was amplified from pSCodon1.2_H6MstXTrCx32 plasmid by PCR using 
two primers - frwAgeIFXaCx32 and revBamHICx32. PCR product was digested with AgeI 
and BamHI DNA restriction enzymes and cloned into pSCodon1.2 vector containing already 
MstX gene (the recipient vector has been produced earlier by Maria Silacheva in our 
laboratory). Final construct is illustrated on Figure 3.12A and have molecular weight of 
48.8 kDa. This construct was designated as MstXTrFXahCx32FXaH8.  
In parallel we generated Cx32 construction without any fusion-tag on N-terminus to 
compare expression rates and to study Mistic influence on Cx32 yield. For this Cx32 gene 
was amplified from pSCodon1.2_MstXTrFXahCx32FXaH8 plasmid by PCR using two 
primers - frwBamHINdeIhCx32 and revBamHICx32. PCR product was digested with NdeI 
and BamHI DNA restriction enzymes and cloned into pSCodon1.2_ 
MstXTrFXahCx32FXaH8 vector. Final construct is illustrated on Figure 3.12B. This 
construct was designated as hCx32FXaH8. Its molecular weight is 34 kDa. 
 
Figure 3.12. Basic features of generated constructs of human connexin 32 gene in fusion with MstX and factor 
Xa protease cleavage site in between - MstXTrFXahCx32FXaH8 (A) and without any fusion-tag on N-terminus - 
hCx32FXaH8 (B). 
3.1.3.2. Expression and purification 
Test expression of Cx32 in fusion with Mistic and without 
Plasmids with both constructs were transformed into SE1 E.coli strain. To compare 
Cx32 expression yields we did test expression in 25 ml of AIM with 100 mg/l ampicillin. 
Bacteria were cultured for 16 h at 37°C with vigorous shaking. Next morning OD600 was 
measured. Normalized volumes of two cultures (2 OD600×ml) were transferred to tubes and 
cells were pelleted down by centrifugation. Each pellet was resuspended in 200 µl of 1× gel-
loading buffer and analyzed by SDS-PAGE and Western-blotting (Figure 3.13). 
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Figure 3.13. Western-blot of total lysates of cells with new Cx32 
constructs (in fusion with Mistic – columns 1, 2; and without – 3, 4) using 
Anti-Connexin32 mouse antibody, anti-mouse lgG alkaline phosphatase 
conjugate and BCIP/NBT enzyme substrate. M: size marker; 1, 3: 10 µl of 
samples was loaded; 2, 4: 20 µl of samples was loaded. 
Since in case of the construct without Mistic no any band was visualized on 
immunoblotting we assumed that expression rate of target protein is extremely low and less 
than 50 ng of connexin were loaded onto the gel. These results are in a good agreement with 
previously reported [11,12]. 
 
“Preparative scale” expression and purification of MstXTrFXahCx32FXaH8. “Two-
detergent” approach. 
Expression was carried out using the standart protocol “E.coli culture and Cx32 
overexpression” described in methods. We again did solubilization screening with several 
detergents, including sodium lauroyl sarcosinate (NLS) – “harsh” ionic surfactant previously 
reported to be effective for solubilization of connexins expressed in E.coli [11]. Observed 
picture was the same as for previous Cx32 constructs in case of all detergents except NLS – 
“harsh” Fos12 solubilized around 50% of Cx32 from total E.coli membranes, while DM, 
Brij35 and others – only about 20%. On the other hand NLS solubilized all the Cx32 and no 
protein was observed in the pellet after centrifugation (data not shown). We carried out 
“preparative scale” solubilization and purification in 1% NLS and noticed that binding 
efficiency of MstXTrFXahCx32FXaH8 (to Ni2+-NTA resin) significantly increased and 90% 
of the solubilized protein was recovered in the eluate. This helped to increase the Cx32 
purification yield up to 1 mg per 1 L of culture. 
Since previously reported data indicate that proteases activity in NLS-containing 
buffers tremendously decreases [173] the only possibility for us was to replace it with other, 
protease-compatible, detergent on the Ni2+-NTA column. To do this washing the resin with 
1% NLS in washing buffer was followed by washing with 1% Brij35. Protein elution was 
carried out in 0.2% Brij35. Unfortunately, analyzing the eluate we did not find Cx32. We 
assumed that all the target protein was stuck on the column. 
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Only combining two detergents on the solubilization stage we recovered the protein in 
the eluate. First, 1% Brij35 was added to a total E.coli membrane suspension. Mixture was 
incubated for 3 h at 4°C with moderate stirring. Next, 1% NLS was added and mixture was 
further incubated overnight. Ni2+-NTA resin was equilibrated with a buffer containing 1% of 
both detergents. Supernatant after centrifugation was loaded on the column; column was first 
washed with 5×CV of washing buffer with 1% NLS and 1% Brij35 and then with 5×CV of 
washing buffer containing only 0.2% Brij35. Finally protein was eluted in 0.2% Brij35. This 
retreat on the purification procedure helped us to recover around 80% of the Cx32 loaded on 
the column. Figure 3.14 demonstrates a typical elution profile with imidazole gradient 30 to 
400 mM. 
 
Figure 3.14. Elution profile of MstXTrFXahCx32FXaH8 from Ni2+-NTA column with imidazole gradient (30-
400 mM) after two washings: with 5×CV of washing buffer containing 1% NLS and 1% Brij35; with 5×CV of 
washing buffer containing only 0.2% Brij35. Fraction numbers are depicted above the x-axis. 
 
 
Figure 3.15. Western-blot of different 
fractions after Cx32 elution with imidazole 
gradient from Ni2+-NTA column. Numbers 
above lanes indicate certain fractions from 
elution profile, shown on Figure 3.14. M: 
size marker. Arrow points to a major 
contaminant band.  
Analysis of corresponding fractions was done by SDS-PAGE and Western-blotting. 
Results are illustrated on Figure 3.15. Although “two-detergent” approach helped to increase 
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yield of target protein it did not solve completely a purity problem (one contaminant band is 
shown by arrow on the picture above). When we collect a middle part of the elution peak only 
40% of Cx32 was recovered after purification, if we collect the whole elution peak – Cx32 
composes less than 50% of total protein in the eluate. To proceed with crystallization 
additional purification step is essential. But since we need to cut-off Mistic to allow connexin 
form proper hexamers we decided first to focus on MstX cleavage. 
 
3.1.3.3. Mistic cleavage tests with factor Xa protease  
As in previous cleavage screenings we first dialyzed the eluate after metal-affinity 
chromatography overnight against 100-fold excess of Factor Xa cleavage buffer (20 mM Tris-
HCl, 50 mM NaCl, 2 mM CaCl2, pH 6.5 with 0.2% of Brij35) at 4°C. Next, samples were 
diluted with the same buffer to a final Cx32 concentration of 0.2 mg/ml. 20 µl aliquots were 
mixed with different amounts of Factor Xa protease (five-fold dilutions starting with a 
maximum protease concentration of 40 U/ml) and incubated overnight at either 20°C or 37°C. 
Further these samples were analyzed by SDS-PAGE and Western-blotting. Results are 
illustrated on Figure 3.16. 
Like with enterokinase or thrombin an excess of Factor Xa protease caused unspecific 
proteolysis while smaller amounts of the protease in the reaction mixture had no effect. 25-
fold excess of Factor Xa protease above the recommended by supplier (1 U per 10 µg of 
protein to be cleaved) caused complete Cx32 degradation at 37°C and more than 50% 
degradation at 20°C (column 1). At the same time the recommended amount of the protease 
had no effect at all (column 3). More detailed screening of protease concentration gave no 
significant improvement. 
Poor cleavage may be caused by steric hindrance when the protease cleavage site is 
too close to ordered structure in the target protein. To overcome this problem we elongated 
the linker between Mistic and connexin 32 by addition of the Strep-tag (WSHPQFEK) 
between the thrombin and Factor Xa cleavage sites (see Figure 3.12A). Then we repeated 
solubilization and purification procedure following “two-detergent” approach. After dialysis 
of Cx32 against the same Factor Xa cleavage buffer samples were mixed with dilutions of the 
protease and incubated overnight at either 20°C or 4°C. Results were visualized by 
immunoblotting (Figure 3.17). 
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Figure 3.16. Western-blot of Cx32 
samples with different FXa protease 
concentrations incubated overnight at 
20°C and 37°C. M: size marker; l: 0.5 
U/μl of FXa; 2:  0.04 U/μl; 3: 8 mU/μl; 
4: 1.6 mU/μl; c: control sample without 
addition of protease; Bands indicating 
unspecific proteolysis are depicted with 
arrows. Anti-Connexin32 mouse 
antibody, anti-mouse lgG alkaline 
phosphatase conjugate and BCIP/NBT 
enzyme substrate were used. 
 
 
Figure 3.17. Immunoblot of Cx32 
samples with different Factor Xa 
concentrations incubated overnight 
at either 20°C or 4°C. M: size 
marker; l: 0.5 U/µl of FXa; 2:  0.04 
U/µl; 3: 8 mU/µl; 4: 1.6 mU/µl; c: 
control sample without addition of 
protease; Major bands indicating 
unspecific proteolysis are depicted 
with arrows. 
 In columns 1 and 2 at both temperatures we again observed unspecific proteolysis and 
degradation of target protein (corresponding bands are depicted with arrows). At the same 
time at lower Factor Xa concentrations in the samples (columns 3 and 4) Mistic was cut-off 
not from all supplied Cx32. Linker elongation caused no significant effect. 
 
3.1.4. Assembling and expression of human connexin 32 gene in fusion with Mistic and 
TEV protease cleavage site in between for in vivo cleavage 
All three proteases described above (EK, thrombin and Factor Xa) show good result in 
case of water-soluble proteins. But there are not so many examples of their successive usage 
for membrane proteins, especially when fusion partner is also membrane protein. On the other 
hand recently it was shown that TEV protease could effectively remove Mistic from the fused 
MstX-NTT1 membrane protein [174].  
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TEV protease is the common name for the 27 kDa catalytic domain of the Nuclear 
Inclusion A (NIa) protein encoded by the tobacco etch virus (TEV). Its sequence specificity is 
far more stringent than that of Factor Xa, thrombin, or enterokinase [175]. For this reason 
TEV protease is widely used for cleaving fusion proteins [176]. Also important to notice that 
it can be easily overproduced and purified in large quantities using E.coli as expression 
system [177]. 
For these reasons we decided to introduce TEV protease cleavage site between Mistic 
and our target Cx32 and to try out in vivo cleavage approach. 
 
3.1.4.1. Cloning strategy 
Cx32 gene was amplified from pSCodon1.2_ MstXTrFXahCx32FXaH8 plasmid by 
PCR using two primers - frwAgeITevhCx32 and revBsrgIhCx32Tev. The PCR product was 
digested with AgeI and BsrgI DNA restriction enzymes and cloned back into pSCodon1.2_ 
MstXTrFXahCx32FXaH8 vector. The final construct is illustrated on Figure 3.18 and has 
molecular weight 50.5 kDa. This construct was designated as MstXTrTevhCx32FXaH8.  
 
Figure 3.18. Basic features of a generated construct of human connexin 32 gene in fusion with MstX and TEV 
protease cleavage site in between. 
3.1.4.2. Expression and purification 
Expression and in vivo cleavage of Cx32 using separate plasmids for TEV protease 
parallel expression 
For expression first pSCodon1.2_ MstXTrTevhCx32FXaH8 vector was transformed 
into SE1 E.coli strain. Next, bacteria were cultured and used for preparation of chemically 
competent cells. Either pRK603 or pKM586 (both are shown on Figure 3.19) containing gene 
of TEV protease were transformed into these cells. Finally, we got SE1 E.coli bacteria, with 
two combinations of plasmids: pSCodon1.2_MstXTrTevhCx32FXaH8 with pRK603 and 
pSCodon1.2_ MstXTrTevhCx32FXaH8 with pKM586.  
Both vectors (pRK603 and pKM586) are intended to be used for controlled 
intracellular processing of fusion proteins (TEV protease substrates) in E.coli [176]. Since 
SE1 strain does not produce Tet repressor expression of the TEV protease gene is constitutive 
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and no induction is needed. Both, pRK603 and pKM586, are low copy plasmids – 10 copies 
per cell are maintained in case of pKM586 and around 30 copies per cell in case of pRK603. 
Test expression was carried out in in 25 ml of AIM with 100 mg/L ampicillin and 
50 mg/L kanamycin. Singe colonies were transferred to media and bacteria were cultured for 
16 h at 37°C with vigorous shaking. Next morning OD600 was measured. Normalized volumes 
of two cultures (2 OD600×ml) were transferred into tubes and cells were harvested by 
centrifugation. Each pellet was dissolved in 200 µl of 1× gel-loading buffer and analyzed by 
SDS-PAGE and Western-blotting (Figure 3.20). 
Both helper plasmids had no influence on the total expression rate of Cx32. But 
unspecific cleavage was observed. Meanwhile pRK603 gave around twice more cleaved 
protein then pKM586. It is perfectly displayed with cleaved monomer bands on Figure 3.20 
(depicted by arrows). 
 
Figure 3.19. Basic features of pKM586 (A) and pRK603 (B) vectors, designed for controlled intracellular 
processing of fusion proteins (TEV protease substrates) in E.coli.  Both vectors were bought from Addgene. 
Although cleavage was not complete we decided to proceed with pRK603 and to try 
expression conditions optimization to achieve Mistic cutting-off from all expressed Cx32. For 
this we tried various cultivation temperatures (20°C, 24°C and 37°C) possessing that 
cultivation temperature might influence TEV protease expression level and folding. At 20°C 
we observed that more Cx32 was cleaved, but there was a drawback – unspecific proteolysis 
also took place and we saw bands corresponding to degraded protein on immunoblots. That is 
why we had to return to standard expression protocol and to cultivate bacteria at 37°C. 
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Figure 3.20. Western-blot of total lysates of cells with new Cx32 construct 
for in vivo Mistic cleavage using Anti-Connexin32 mouse antibody, anti-
mouse IgG alkaline phosphatase conjugate and BCIP/NBT enzyme substrate. 
M: size marker; 1: 20 µl of sample with pKM586; 2: 20 µl of sample with 
pRK603; 3: 20 µl of control sample without TEV protease containing 
vectors. Bands corresponding to cleaved Cx32 monomer are depicted with 
arrows. 
Purification of solubilized Cx32 using Ni2+-NTA agarose 
“Preparative scale” expression was carried out as described in methods. Cx32 was 
solubilized using “two-detergent” approach in 1% Brij35 and 1% NLS. Before applying to 
Ni2+-NTA pre-packed column supernatant after centrifugation was diluted with equal volume 
of the same buffer to reduce NLS and solubilized proteins concentrations. This helped to 
increase binding efficiency so that only 20% of Cx32 flowed through the column. Further the 
column was washed with 5×CV of washing buffer with 1% NLS and 1% Brij35 and then with 
5×CV of washing buffer containing only 0.2% Brij35. Finally protein was eluted in 0.2% 
Brij35. Typical elution profile is illustrated on Figure 3.21. 
 
Figure 3.21. Elution profile of MstXTrTevhCx32FXaH8 coexpressed with TEV protease from Ni2+-NTA 
column with imidazole gradient (30-400 mM) after two washings: with 5×CV of washing buffer containing 
1% NLS and 1% Brij35; with 5×CV of washing buffer containing only 0.2% Brij35. Fraction numbers are 
depicted above the x-axis. 
Analysis of eluate fractions demonstrated that Ni2+-NTA agarose did not allow 
separating of Cx32 from not-cleaved Mistic-Cx32. Corresponding Western-blot is showed on 
the Figure 3.22. 
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Figure 3.22. Western-blot of different 
fractions after Cx32 elution with 
imidazole gradient from Ni2+-NTA 
column. Numbers above lanes indicate 
certain fractions from elution profile, 
shown on Figure 3.21. M: size 
marker. Arrows depict monomer 
bands corresponding to cleaved and 
not cleaved Cx32. 
 
Ion exchange chromatography to separate cleaved and not cleaved Cx32 
Since isoelectric point of Mistic (pI=4.5) and connexin 32 (pI=9.2) differs 
significantly we assumed that ion exchange chromatography would perfectly fit to separate 
cleaved and not cleaved Cx32. As cation and anion exchangers, MonoS and MonoQ, 
respectively, were considered. Both of them are incompatible with charged ionic surfactants. 
For this reason all experiments were carried out with Cx32 solubilized in relatively “soft” 
detergent – Brij35.  
Prior to application to both columns eluates after Ni2+-NTA purification were dialyzed 
against buffers recommended by supplier containing 0.2% Brij35 (see methods).  Protein was 
eluted in raising concentration of NaCl from 0.05 M up to 1 M in 20×CV. Fractions were 
collected and further analyzed by SDS-PAGE and Western-blotting. Multiple elution peaks 
obtained were very similar regarding to ratio between uncleaved Mistic-Cx32 and cleaved out 
Cx32 product. Connexin with Mistic and cleaved connexin appeared to form complexes (or 
oligomerized) by means of hydrophobic interactions. And for this reason salt cannot help to 
separate them. 
“Harsh” ionic surfactants (NLS or SDS) can harm our protein and reduce separation 
efficiency of ion chromatography. For this reason we could not use them to eliminate 
hydrophobic interactions between cleaved and not cleaved Cx32. Since urea and guanidine 
hydrochloride are widely used for denaturation of proteins and as a mild solubilization 
agent we decided to screen their influence in our case. We varied urea (from 1 M up to 8 M) 
and guanidine hydrochloride (from 0.5 M up to 6 M) concentrations in equilibration and 
elution buffers. On Figure 3.23 elution profile in case of MonoQ is shown when 6 M urea 
was added to the equilibration buffer.  All fractions were collected and analyzed by 
immunoblotting (Figure 3.24).  
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Figure 3.23. Elution profile of MstXTrTevhCx32FXaH8 coexpressed with TEV protease from MonoQ column 
with salt gradient (0-1 M NaCl). Loaded protein was preliminary purified using “two detergent” protocol on 
Ni2+-NTA agarose and dialyzed against MonoQ equilibration buffer (20 mM Tris-HCl, 6 M urea, 0.2% Brij35, 
pH 8.0). Fraction numbers are depicted above the x-axis. 
Addition of urea and guanidine hydrochloride had no noticeable influence on 
separation of processed and not Cx32. Connexin was detected in both states in all eluate 
fractions. This meant that the only possibility to get connexin without Mistic in case of TEV 
protease cleavage was to achieve complete processing in vivo. 
 
Figure 3.24. Immunoblot of different 
fractions after Cx32 elution with NaCl 
gradient (0-1 M) from MonoQ column. 
Numbers above lanes indicate certain 
fractions from elution profile, shown on 
Figure 3.23. M: size marker. 
 
Co-expression of TEV protease and connexin 32 
Since helper plasmid pRK603 with higher amount of copies per cell showed better 
results than pKM586 we decided to introduce TEV protease into pSCodon1.2 (high copy 
plasmid) already containing Cx32 gene. TEV protease gene was also controlled with lac 
operon, which meant that it would be expressed in parallel to connexin. The resulting 
construct is illustrated on Figure 3.25. 
Unfortunately, TEV protease expression rate turned out to be too high and toxic effect 
was observed. Also analysis showed that total Cx32 yield was 3 times lower in comparison to 
usage of helper plasmid.  
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Figure 3.25. Basic features of a new construct for co-expression of connexin 32 and TEV protease. TEV 
protease gene was cloned into pSCodon1.2 containing already connexin 32 gene.  
 
3.2. Cell free expression of human connexin 32 using S30 E.coli extract 
Structural study of membrane proteins is a complex task and problems may appear on 
each step. Purification of large quantities of membrane proteins always was essential for 
crystallization experiments. In spite of recent advances in nano-volume crystallization 
milligram amounts of a purified membrane protein are still required. At present, one of the 
most preferred heterologous expression system is E.coli, which is both time-consuming and 
has the limitation of producing membrane proteins, in particular those of eukaryotic origin. 
Although recent improvements using engineered strains and protein fusion partners have led 
to improved production of insoluble proteins, such approaches are generally not universal and 
require optimization in each individual case. Cell-free protein synthesis (CFPS) is emerging 
as an attractive alternative since it offers a simple, open and flexible approach to rapid 
synthesis of folded proteins. The use of PCR fragments, avoiding the need for in vivo cloning, 
gives cell-free systems even greater usefulness for parallel expression of large numbers of 
different proteins. It is also capable of functionally producing both disulphide-bonded and 
membrane proteins, providing a platform for generation of “difficult-to-express” proteins 
[178]. In case of membrane proteins (MPs) CFPS can help to eliminate some principal 
problems occurring in conventional in vivo systems, like toxicity of the overproduced MPs 
upon insertion into the cytoplasmic membranes, poor growth of overexpressing strains, 
proteolytic degradation of the expressed MPs, or generally unfavorable impacts on cellular 
metabolisms. Also, it was previously reported that in case of CFPS genes with native codon 
usage had as high a yield as optimized codon usage [179,180]. This means that no codon 
optimization is required for effective heterologous expression in CF. 
pSCodon1.2_ TeV-MTrStrTeVhCx32FXaH8,  8.0kb 
ori ColE1 AmpR 
hCx32 Mistic TR T7 lacO H8 Str TeV FXa 
T7 lacO TeV 
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Although we showed that overexpression of connexin 32 using Mistic as fusion partner 
is possible, we did not succeed in its cleavage from N-terminus of our connexin. We 
demonstrated that MstX is resistant to various cleavage conditions including different 
proteases usage and variations of linker in between. For this reason appropriate system to 
produce milligram amounts of Cx32 without any N-terminal additives is needed. And such 
system was reported to exist – in 2010 G. Chang et al mentioned that connexin 32 might be 
overexpressed in CFPS using E.coli extract [181]. For these reasons we decided to use cell 
free protein expression system to overexpress connexin 32. 
 
3.2.1. Cx32 gene optimization 
Since CFPS is more expensive than usual in vivo expression every milligram of 
produced protein is on account. First we decided to perform test expression of several human 
connexins to know which protein yield we expect.  
To do test expression we cloned our Cx32 into pivex2.3d vector, specially designed 
for CFPS. Briefly, Cx32 gene was digested from pSCodon1.2_hCx32FXaH8 plasmid with 
NdeI and XhoI DNA restriction enzymes and cloned into empty pivex2.3d vector. Final 
construct had molecular weight 34 kDa and was designated as pivex2.3d_hCx32FXaH8.  
Constructs with 3 other connexins (Cx26, Cx30.2 and Cx40) were generated by Taras 
Balandin and Dmytro Volkov in our laboratory. 
Plasmids were produced and purified in sufficient for CFPS amounts following the 
procedure “plasmid DNA purification for cell free protein synthesis” described in Methods. 
The expression was carried out in the “analytical scale” reaction setup with Mg2+ 
concentration 14 mM, K+ – 290 mM and 1% Brij58. After overnight incubation at 32°C 
reactions were terminated. Reaction mixtures were centrifuged at 18000×g for 20 min at 4°C 
to remove precipitants and insoluble additives. 1 µl of supernatant from each chamber was 
mixed with 1× gel-loading buffer and analyzed by SDS-PAGE and immunoblotting (to 
identify bands corresponding to connexins anti-His6 primary antibodies were used). The 
resulting gel is shown on Figure 3.26. 
It appeared that in case of optimized for E.coli Cx26 gene (oCx26) expression rate 
was slightly higher then for wild-type gene (Cx26). To find out whether there exists any 
correlation between free energy of connexin mRNA secondary structure and CFPS yield we 
built diagram, illustrated on Figure 3.27. Thus, it is obvious that certain connexin yield from 
CFPS strongly depends on free energy of its mRNA secondary structure. Small deviation in 
case of Cx30.2 may be explained by big loop in the beginning of its mRNA. 
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Figure 3.26. Coomassie-stained SDS gel for 
analysis of different human connexins 
expression rates in CFPS. 1 µl of each 
reaction mixture was loaded. M: size marker; 
1, 2: number of reaction chamber (for each 
construction two reaction chambers were 
used). Monomer bands for each connexin are 
marked. Positions of monomers bands were 
identified using immunoblot with anti-H6 
primary antibodies. 
Based on these results we did optimization of connexin 32 gene sequence, which 
helped us to reduce free energy more than twice (from -222 kkal/mol to -97.1 kkal/mol). 
Optimized oCx32 gene was synthesized by MWG, Ebersberg, Germany and cloned into 
pivex2.3d vector using NdeI and XhoI DNA restriction sites. Final construct had molecular 
weight 34.4 kDa and was designated as pivex2.3d_ohCx32FXaH10. 
Despite such significant reduction of free energy control expression experiment with 
Cx32 and oCx32 showed only 30% yield increase in case of optimized gene (total connexin 
32 yield was 0.3 mg of protein per 1 ml of reaction mixture). 
 
Figure 3.27. Connexins expression rates in 
CFPS and free energy of their mRNA 
secondary structures (both normalized). 
Protein yield was calculated from intensities 
of monomer bands on SDS-PAGE gel. Free 
energy of mRNA secondary structure was 
calculated using GeneBee service. 
 
3.2.2. N-terminal tags to increase Cx32 yield 
In 2012 S. Haberstock et al showed that addition of short N-terminal tags (7 amino 
acids) could result in significant (reported 32-fold) CFPS yield improvement in case of 
membrane proteins [182]. Observed results were explained by optimization of translation 
initiation. 
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To use this approach we first designed construct with N-terminal polyhistidine-tag. 
Briefly, oCx32 gene was amplified from pixev2.3d_ohCx32FXaH10 vector by PCR using two 
primers - frwM1GCx32 and revXhoIohCx32. M1G mutation was introduced to improve 
cleavage with Factor Xa protease in case of successful overexpression. PCR product was 
digested with SacII and XhoI DNA restriction enzymes and cloned into empty pivex2.4d 
vector. Final construct is illustrated on Figure 3.28 and have molecular weight 33.8 kDa. This 
construct was designated as pivex2.3d_H6FXaM1GoCx32. 
 
Figure 3.28. Basic features of a new construct for CFPS expression of connexin 32. Cx32 gene sequence was 
optimized to reduce free energy of mRNA secondary structures. M1G mutation was introduced to improve 
cleavage with Factor Xa protease.  
Short peptides, listed in Table 3.1, were introduced to N-terminus of 
H6FXaM1GoCx32 by circular PCR using two corresponding primers and 
pivex2.3d_H6FXaM1GoCx32 as a template. PCR products were purified, ligated and 
transformed into TOP10 E.coli competent cells. After production and purification of 
sufficient amounts of resulting plasmids we carried out expression experiment in the 
“analytical scale” reaction setup with Mg2+ concentration 14 mM, K+ – 290 mM and 1% 
Brij58. After overnight incubation at 32°C reactions were terminated. The reaction mixtures 
were centrifuged at 18000×g for 20 min at 4°C to remove precipitants and insoluble additives. 
The supernatants were analyzed as before by SDS-PAGE (Figure 3.29). 
In our case addition of N-terminal expression enhancers had no significant effect. 
Cx32 yields (monomer bands intensities) were almost the same as for initial construct (H6) 
with small deviations. Yield in case of C-terminal polyhistidine-tag (H10) was two times 
higher. 
Construct Tag sequence Primers combination 
pivex2.4_AT-H6FXaM1GoCx32 MKYYKYY frw_AT_H6 and rev_RBS_T7 
pivex2.4_Ser-H6FXaM1GoCx32 MKSSSSS frw_SER_H6 and rev_RBS_T7 
pivex2.4_G-H6FXaM1GoCx32 MKSKGEE frw_G_H6 and rev_RBS_T7 
pivex2.4_H-H6FXaM1GoCx32 MKPYDGP frw_H_H6 and rev_RBS_T7 
 
Table 3.1. List of primers combinations and N-terminal tags sequences used to generate new constructions to 
enhance expression rate of Cx32 in CFPS. 
 
His6 
purification tag 
M1GoCx32, pI=9.2 
GNWT…CSAC 
site for 
FXa 
IEGR| 
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Figure 3.29. Coomassie-stained SDS gel for analysis of N-terminal tags influence on Cx32 expression rates in 
CFPS. 1 µl of each reaction mixture was loaded. M: size marker; 1, 2: number of reaction chamber (for each 
construction two reaction chambers were used); AT, Ser, H, G: constructions with N-terminal expression 
enhancers; H6: pivex2.3d_ H6FXaM1GoCx32; H10: pivex2.3d_ ohCx32FXaH10. With arrow monomer bands are 
depicted. Positions of monomers bands were identified using immunoblot with Anti-Connexin32 mouse 
antibodies. 
On this point we decided to stop “playing” with DNAs and to proceed to expression 
conditions screens (vary detergents and add lipids to CFPS reaction mixture). 
 
3.2.3. Detergent screen to increase Cx32 yield 
In CFPS membrane proteins can be produced either as a precipitate or as solubilized 
proteins. The CF expression system is considerably tolerant upon relatively high 
concentrations of a variety of detergents and lipids [183–185] that usually are provided as a 
hydrophobic environment to stabilize the synthesized MPs immediately after translation. 
Alternatively, the vast majority of MPs are produced as precipitates if detergents are not 
supplemented. However, those precipitates usually can easily be solubilized with suitable 
detergents without the necessity to apply extensive denaturation and renaturation steps as 
known from refolding protocols.  
Addition of suitable detergent or lipid to CPFS can play important role in terms of 
MPs yield [183]. To find optimal conditions for Cx32 overexpression we screened several 
detergents. Concentration of each detergent which did not suppress CF protein production 
were previously reported in [162]. In our experiment we used 8 detergents: 1.5% Brij35, 
1.5% Brij 58, 1% Brij78, 0.4% Digitonin, 0.1% Triton X-100, 0.1% DM, 0.1% DDM, 0.1% 
Tween20. Reactions were carried out in “analytical scale” setup with Mg2+ concentration of 
14 mM and K+ of 290 mM. After overnight incubation at 32°C reactions were terminated. 
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The reaction mixtures were centrifuged at 18000×g for 20 min at 4°C to remove precipitants 
and insoluble additives. As before, the supernatants were analyzed by SDS-PAGE (Figure 
3.30A). From intensities of monomer bands we calculated approximate Cx32 yields for each 
detergent. Normalized expression rates are shown on Figure 3.30B. 
 
Figure 3.30. Detergents influence on Cx32 yields from CFPS. (A) Coomassie-stained SDS gel for analysis of 
detergents influence on Cx32 expression rates in CFPS. 1 µl of each reaction mixture was loaded. M: size 
marker; 1: Brij35 1.5%; 2: Brij58 1.5%; 3: Brij78 1%; 4: Digitonin 0.4%; 5: Triton X-100 0.1%; 6: DM 0.1%; 7: 
DDM 0.1%; Tween20 0.1%; 9: proteorhodopsin expression in Digitonin 0.4%; PM: pellet mod (without addition 
of any detergent). Cx32 monomer bands are depicted with arrow. (B) Normalized Cx32 yields from CFPS with 
different detergents. Protein yields were calculated from intensities of monomer bands on SDS-PAGE gel. 
  Although tremendous detergent influence was not observed, digitonin and Brij78 
demonstrated best results – 20% Cx32 yield increase. Expression rates in case of Brij35, 
Brij58 and Tween were almost the same. DM, DDM and Triton X-100 suppressed CF 
production of Cx32 more significantly. But because of availability problems for “preparative 
scale” expression and further studies we had to choose Brij58 (Brij78 was not available in 
sufficient for “preparative scale” setup quantities in our laboratory; digitonin was too 
expensive and was increasing the final cost of 1 ml CFPS reaction mixture more than twice). 
 
3.2.4. Lipids and lipid/detergent mixtures in CFPS of Cx32 
To study lipids influence on Cx32 yield from CFPS we screened several 
concentrations of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). Dry POPC 
powder was dissolved in chloroform and then dried overnight under nitrogen gas. Lipid film 
was rehydrated in S30 buffer (see methods) at concentration 100 mg of lipid per 1 ml of 
buffer (10% stock), and the suspension was warmed to 37°C until it became transparent. 
Next, as in case of detergents, certain amounts of this stock were added to CF reaction 
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mixtures to obtain desirable final concentration (0.05%, 0.2% and 0.4%). Addition of above 
0.4% of lipids was previously reported to significantly suppress CF protein production. 
Reactions were carried out in “analytical scale” setup with Mg2+ concentration of 14 mM and 
K+ of 290 mM. After overnight incubation at 32°C reactions were terminated. The reaction 
mixtures were centrifuged at 18000×g for 20 min at 4°C. The pellets were resuspended in 
50 µl of 1×	 gel-loading buffer and analyzed by SDS-PAGE (this time we analyzed only 
pellets, since we were interested in Cx32 incorporated into membranes). The resulting 
polyacrylamide gel is illustrated on Figure 3.31A. 
 
Figure 3.31. Lipids and lipid/detergent mixtures influence on the Cx32 yields from CFPS. (A) Coomassie-
stained SDS gel for analysis of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) influence on Cx32 
expression rates in CFPS. (B) Coomassie-stained SDS gel for analysis of POPC/Brij58 and POPC/DDM 
influence on Cx32 expression rates in CFPS. For both gels 1 µl of each reaction mixture was loaded. M: size 
marker; PM: pellet mode. Cx32 monomer bands are depicted with arrow. With red triangles Cx32 yield behavior 
is illustrated. 
After incubation in reaction mixtures with liposomes we observed noticeable turbidity. 
This might mean that during reaction multilamellar liposomes were formed. These liposomes 
excluded certain volume of reaction components from mixture thus resulting into expression 
efficiency decrease.  Observed Cx32 production levels in the samples with lipids were 30% 
lower than in the control sample with 1.5% Bij58. Increase of POPC concentration in the 
reactions resulted in the Cx32 yield decrease. In pellet mode (PM), when no detergent or lipid 
was added to the mixture, protein yield was almost equal to those from mixtures with POPC. 
To overcome formation of liposomes in reaction mixtures we added combination of 
lipids with excessive amounts of detergent. We assumed that such combination would supply 
lipid/protein interface helping proper Cx32 folding while lipids would be solubilized in 
detergent micelles and would not form bilayer. 10% POPC stock solution was mixed with 
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20% detergents stocks (DDM and Brij58) in the same S30 buffer with certain ratio 
(POPC/Brij58 – 1/1, 0.8/1, 0.6/1, 0.4/1, 0.2/1, 0.1/1; POPC/DDM – 1/1, 0.5/1, 0.25/1, 0.15/1, 
0.1/1), extruded though 50 nm filter and added to CF reaction mixtures. Reactions were 
carried out in analytical scale setup with Mg2+ concentration of 14 mM and K+ of 290 mM. 
After overnight incubation at 32°C reactions were terminated. The reaction mixtures were 
centrifuged at 18000×g for 20 min at 4°C. This time no turbidity was observed, so only the 
supernatants were analyzed (Figure 3.31B). 
In case of POPC/Brij58 combination the same tendency (as only with POPC) was 
observed – higher amounts of lipids suppressed Cx32 production more significantly. In case 
of POPC/DDM mixtures we saw opposite effect, addition of lipids enhanced Cx32 
production. This might be explained by higher toxic effect of DDM on CFPS (then Brij58), 
which was reduced by lipids addition. Nevertheless, both combinations did not show any 
significant Cx32 yield increase in comparison to addition of only Brij58. For this reason we 
stopped screening experiments and proceeded to further protein production and purification. 
 
3.2.5. Expression and purification of Cx32 from CFPS 
For “preparative scale” reactions slide-A-lyzer setup (with 14kDa cut-off membrane) 
was used (see Figure 2.2b from methods) and the mixture was incubated at 32°C overnight 
with gentle stirring (120 rpm). For “preparative scale” CF expression of Cx32 we added 
14 mM Mg2+, 290 mM K+ and 1.5% Brij58 into the mixture. Next morning the reaction was 
terminated. The reaction mixture was discarded and centrifuged at 18000×g for 20 min at 4°C 
to remove precipitants and insoluble additives. The supernatant was collected and applied 
onto PD10 desalting column pre-equilibrated with desalting buffer (20 mM Tris-HCl, 
100 mM NaCl, pH 7.5 + 1% Brij58). Next, the eluate was loaded onto column pre-packed 
with Ni2+-NTA and pre-equilibrated with the same buffer. The column with bound protein 
was washed with 5×CV of washing buffer containing 1% Brij58. Cx32 was eluted with 
elution buffer containing 1% Brij58. First experiments with Brij58 showed that only 20% of 
Cx32 was recovered in eluate, all the rest was found in the flow through. 
 To increase binding efficiency we screened three other detergents: quite “harsh” NLS 
and SDS as well as suitable for further crystallization DDM. 0.5% of each surfactant was 
added to the removed from slide-A-lyzer reaction mixture. The resulting sample was 
incubated for 1 h at 32°C with gentle stirring and then centrifuged at 18000×g for 20 min at 
4°C. Purification protocol was completely repeated; Brij58 was replaced with 0.5% NLS, 
SDS or DDM in all buffers. The best result was observed in case of NLS – all Cx32 from the 
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reaction mixture was recovered in the eluate, no Cx32 was found in the flow through. Final 
connexin purity was 80%. When we used SDS and DDM only 50% of Cx32 was recovered in 
the eluates, the rest either unfound or not eluted from Ni2+-NTA resin. 
 N-lauroyl sarcosine is interfering with further crystallization. To replace it with more 
suitable DDM or SDS we used gel-filtration. The eluate after metal-affinity chromatography 
was applied to Superose6HR 24 ml column pre-equilibrated with equilibration buffer 
containing either 0.2% DDM or 0.2% SDS. The elution profiles are illustrated on Figure 
3.32. For both detergents only 20% of Cx32 was recovered in the eluates. The rest was either 
found in the free volume (aggregated) or was stuck on the column. It is important to notice 
that Cx32 was eluted in SDS in one broad peak at 13.5 ml, which corresponded to the 
characteristic size of connexin hemichannel (200 kDa). But, since peak was much broader 
than for globular proteins used for calibration we concluded that variety of oligomeric states 
were present in the eluate. The similar picture was seen for the eluate in DDM - different 
oligomeric states were observed although most of Cx32 ran as monomer (peak at 17 ml). 
Anyway, gel-filtration allowed Cx32 transferring from NLS to neither SDS nor DDM, since 
too much protein of interest was lost. 
 
Figure 3.32. Size-exclusion chromatography to replace 0.5% NLS with 0.2% SDS (red) or 0.2% DDM (blue). 
Cx32 in 0.5% NLS was loaded onto pre-equilibrated with appropriate detergent Superose6HR 24 ml column and 
eluted in the same buffer with 0.1 ml/min flow speed. Grey lines correspond to calibration with globular 
proteins. 
The expertize-dependent solution was to try replacing detergent before elution from 
Ni2+-NTA resin. For this purpose NLS in washing and elution buffer was replaced for either 
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0.5% SDS or 0.5% DDM. In case of DDM no Cx32 was found in the eluate, which indicated 
that all connexin stuck on the resin. While in SDS all Cx32 was recovered in the eluate with 
final purity more than 90% (Figure 3.33). For further experiments purification protocol with 
elution in 0.5% SDS was chosen.  
 
Figure 3.33. Coomassie-stained SDS gel for analysis of Cx32 purity after 
metal affinity chromatography. M: size marker; 1, 2 and 3: different eluate 
fractions. Bands, corresponding to different Cx32 oligomers (monomer, dimer 
and trimmer) are depicted with arrows. 
3.2.6. Refolding of Cx32 
For usual vapor diffusion crystallization approach homogeneous protein preferably 
solubilized in suitable detergent, which stabilize its correct folding, is required. Almost the 
same situation is in case of in meso crystallization, except that membrane protein may be 
supplied in lipids, i.e. reconstituted into lipids. For connexins, since we are interested in 
crystallization of hemichannel, homogeneity means not only high protein purity, but also 
absence in the sample supplied for crystallization other oligomeric states except hexamers.  
As was showed above in SDS Cx32 does not tend to form stable hemichannels and 
variety of oligomeric states can be observed. Also SDS is quite “harsh” detergent and one 
cannot consider that it’s able to stabilize proper connexin folding. For this reason SDS must 
be replaced with either lipid or suitable for crystallization “mild” detergent. Lipids have 
crucial structural and modulatory effect on connexins. Certain phospholipids are tightly 
associated with connexin channels and are co-purified with connexins when “mild” detergents 
are used for solubilization. This fact was previously reported and since then confirmed several 
times [186]. Usage of “harsh” NLS and SDS in our purification protocol allows us to assume 
that all lipids are washed away from Cx32 and none are associated with protein. But this 
means that for proper hemichannel formation we possibly need to supply certain lipids to our 
sample. 
But there exits the alternative. Quite recently new polymers were introduced – 
amphipols (in this study A8-35 was used), amphipathic polymers developed for handling MPs 
in aqueous solutions under less destabilizing conditions than those of detergent solutions. 
They have proved to be efficient tools for folding MPs to their native state starting from a 
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denatured state in SDS or urea [166,187]. Furthermore, in aqueous solutions A8-35 does not 
form bilayers (like lipids), but forms globular particles that resemble detergent micelles. Upon 
associating with MPs, it covers their transmembrane surface with an amphipathic layer thus 
stabilizing MPs. Also, recent studies showed that bacteriorhodopsin (BR) from 
Halobacterium salinarum trapped in A8-35 can be crystallized using in meso approach 
(unpublished). Unfortunately, A8-35 cannot support in vitro MP synthesis [188,189]. This 
may be related to the observation that charged detergents tend to block MP CFPS [183]. 
To refold Cx32 solubilized in SDS in A8-35 we first decided to use dialysis. To Cx32 
after elution from Ni2+-NTA column and dialysis against buffer without imidazole but with 
0.1% SDS amphipol was added at the ratio 10 g of A8-35 per 1 g of SDS-unfolded connexin. 
The mixture was incubated for 30 minutes at room temperature and then was loaded into 
slide-A-lyzer (with membrane cut-off 20 kDa) and dialyzed against 100-fold excess of 
refolding buffer (20 mM Tris-HCl, 100 mM NaCl, 1 mM KCl, pH 7.5) at 4°C overnight.  
Aggregates and precipitated SDS were removed by centrifugation at 20000×g for 20 min at 
4°C. Analysis of the supernatant and the pellet after this centrifugation by SDS-PAGE 
showed refolding efficiency of only 20%. This means that 20% Cx32 was still present in the 
supernatant, while the rest 80% were found in the pellet. Similar result was reported for BR 
refolding in A8-35 [166], so we decided to try another approach. 
In case of amphipol mediated refolding of GPCR and BR much better results were 
obtained with PDS precipitation form protein/SDS/A8-35 solution by addition of potassium 
chloride. Refolding of Cx32 form SDS in amphipol was done by stepwise addition of 
1 M KCl stock solution to the protein suspension. The same procedure as described above 
was used. Only instead of dialysis after short incubation at room temperature the sample was 
kept on ice and KCl was added by small portions to a final concentration of 100 mM. 
Precipitated PDS was removed by centrifugation at 20000×g for 20 min at 4°C. Analysis of 
the supernatant and the pellet by SDS-PAGE showed that all Cx32 remained in the 
supernatant. Further the supernatant was analyzed by size exclusion chromatography. For this 
it was applied to Superose6HR 24 ml column pre-equilibrated with equilibration buffer 
without any detergent. Resulting chromatogram is shown on Figure 3.34 in red. Initial Cx32 
solubilized in SDS before detergent precipitation is depicted with blue. Cx32 refolding to A8-
35 caused significant peak narrowing in comparison to Cx32/SDS sample. The width of this 
peak was the same as reported previously for Cx32 solubilized from gap junctional plaques. 
Therefore amphipol helped us to assemble Cx32 hemichannel and to produce homogeneous in 
terms of oligomerization sample, suitable for further crystallization. 
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Figure 3.34. Size-exclusion chromatography of Cx32 solubilized in 0.5% SDS (blue) and then refolded in 
amphipol A8-35 (red) by SDS precipitation as its potassium salt. Cx32 in 0.5% SDS after purification by metal 
affinity chromatography was loaded onto pre-equilibrated with equilibration buffer (with the same SDS 
concentration) Superose6HR 24 ml column and eluted in the same buffer with 0.1 ml/min flow speed. For 
refolded in A8-35 connexin 32 equilibration buffer without any detergent was used. Grey lines correspond to 
calibration with globular proteins. With green elution profile of Cx32 overexpressed in Sf-9 insect cells is shown 
(not hemichannels but gap junctions) [16]. 
 
3.3. E.coli expression of optimized connexin 32 gene 
In parallel to the experiments on CF connexin 32 synthesis we carried out test 
expression of optimized Cx32 gene in E.coli. First, optimized Cx32 gene with N-terminal 
polyhistidine tag was cloned from pivex2.3d_H6FXaM1GoCx32 using XbaI and XhoI DNA 
restriction sites into empty pSCodon1.2 vector. Resulting plasmid was transformed into SE1 
E.coli strain and test expression was carried out same as it was described in section 3.1.1.2. 
Results indicated that in case of optimized Cx32 gene expression level was significantly 
higher in comparison to non-optimized pSCodon1.2_hCx32FXaH8 construct. In order to 
understand whether Cx32 gene optimization or N-terminal polyhistidine tag helped to 
enhance expression we decided to prepare construct with optimized Cx32 gene and C-
terminal affinity tag. Same procedure as described above was used. Briefly, optimized Cx32 
gene with C-terminal polyhistidine tag was cloned from pivex2.3d_ohCx32FXaH10 using 
XbaI and XhoI DNA restriction sites into empty pSCodon1.2 vector. Resulting plasmid was 
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transformed into SE1 E.coli strain and again test expression was carried out. Cx32 expression 
yield was the same as for construct with N-terminal affinity tag, which indicated that gene 
optimization played crucial role in expression enhancement. Observed Cx32 yield was 0.5 mg 
of protein per 1 L of culture (before purification) and since E.coli expression is much cheaper 
than CFPS we decided to shift our attention to it. 
“Preparative scale” expression was carried out as described in section 2.2.3 of materials 
and methods with small deviations. Briefly, one colony of freshly transformed bacteria was 
grown overnight at 37°C in 50 ml of LB broth with 1% glucose and 100 mg/l ampicillin in 
500 ml flask. Next morning 0,5 L of AIM without 5052 but with 1% glucose and antibiotic 
was inoculated with this overnight culture and was grown at 37°C for approximately 9 h in 
2 L flask. When glucose in pre-culture was depleted 6 L of AIM with 100 mg/l ampicillin 
were inoculated with this pre-culture at starting OD600 around 0.2. The bacteria were cultured 
in 2 L flasks at 37°C with vigorous shaking (120 rpm). Glucose level in media was controlled 
by commercial glucose tests (Merckoquant®). When glucose was depleted (around 3-4 h after 
inoculation), culture was cooled to 20°C for overnight incubation. The cells were harvested 
by centrifugation at 5000×g for 30 min at 4°C and then either immediately used for protein 
purification or frozen in liquid nitrogen and stored at -80°C.  
 
3.3.1. Purification in NLS/SDS and further Cx32 refolding 
Bacterial pellets (around 30 g) were resuspended in 150 ml of ice-cold 10% glycerol 
solution. Deoxyribonuclease I from bovine pancreas was added to cleave DNA in the cell 
suspension after lysis (0.6 mg of DNAse per 30 g of cells). First, the cells were disrupted by 
passing through the microfluidizer precooled at 4°C with one pass. Next, NaOH was added to 
mixture to final concentration 20 mM. The solution was incubated for 30 min on ice with 
vigorous mixing. Then, it was passed through the precooled microfluidizer two additional 
times. The suspension was centrifuged at 120000×g for 1 h at 4°C (Beckman Ti70 rotor) to 
separate E.coli total membranes. The supernatant was discarded; the pellet was resuspended 
in 150 ml of ice-cold homogenization buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.5). To 
wash out membrane associated proteins and some lipids we used 1% Triton X-100. It was 
added to the membrane suspension, which were next incubated for 1 h at 4°C with vigorous 
mixing. The washed membranes were collected by centrifugation at 120000×g for 1 h at 4°C 
and again resuspended in 150 ml of the same homogenization buffer. For Cx32 solubilization 
1.5 g of NLS was added to the suspension (1%) and mixture was incubated overnight at 4°C 
with vigorous mixing. 
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Next morning the suspension was centrifuged at 120000×g for 1 h at 4°C to remove 
insoluble material. The supernatant containing solubilized proteins was first diluted with 
solubilization buffer to reduce NLS concentration to 0.5%, 20 mM Imidazole was added to 
increase binding specificity. Then this mixture was added to 3 ml of pre-equilibrated Ni2+-
NTA beads (with solubilization buffer containing 0.5% NLS) and incubated at 4°C for 5 h 
under gentle rotation. The resin with bound protein was loaded onto chromatographic column 
and further washed with 5×CV of washing buffer (20 mM Tris-HCl, 100 mM NaCl, 20 mM 
Imidazole, 0.5% NLS, pH 7.5) using AKTA purifier chromatographic system. Next washing 
step was carried out to exchange NLS for SDS. For this purpose the column was washed 
additionally with 5×CV of washing buffer, containing 0.2% SDS. Finally, bound proteins 
were eluted in 2×CV of elution buffer (20 mM Tris-HCl, 100 mM NaCl, 400 mM Imidazole, 
0.2% SDS, pH 7.5). The purification on chromatographic system was done at room 
temperature (since SDS precipitated under lower temperatures). 
 
3.3.1.1. Refolding of Cx32 from SDS 
First, we decided to screen several detergents for their ability to stabilize proper Cx32 
refolding and its oligomerization. 9 detergents with 5×CMC concentrations (0.05% DDM, 
0.05% DDM/CHS, 1.24% Cymal-5, 0.26% Fos12, 0.23% LDAO, 0.28% F6TAC8.5, 0.13% 
F6DiGluM, 0.09% HTAC and 0.15% A8-35) were added to the eluates of Cx32 in 0.2% SDS 
after affinity chromatography. As before, after 1h incubation of these mixtures at room 
temperature they were cooled down on ice. Refolding of Cx32 form SDS was done by 
stepwise addition of 1 M KCl stock solution to the protein solution. Small portions of KCl 
were added to final concentration of 100 mM. Precipitated potassium dodecylsulphate was 
removed by centrifugation at 20000×g for 20 min at 4°C. Analysis of the supernatants and the 
pellets by SDS-PAGE showed that in case of 5 detergents (DDM, DDM/CHS, Fos12, 
F6DiGluM, A8-35) all Cx32 remained in the supernatant. For the rest – connexin precipitated 
together with PDS and no protein was found in the supernatants after centrifugation. 
Further the supernatants with Cx32 were analyzed by size-exclusion chromatography 
using Superose6HR 24 ml column pre-equilibrated with equilibration buffer (20 mM Tris-
HCl, 100 mM NaCl, 1mM EDTA, 1 mM EGTA, pH 7.5) containing 1×CMC of these 5 
detergents. Resulting chromatograms indicated that in all cases except A8-35 Cx32 
aggregated and migrated through the column either in the void volume or as big particles of 
size over then 720 kDa (with peak elution volumes between 6 and 10 ml). In case of amphipol 
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– peak was left shifted and a little wider comparing to initial sample in SDS (Figure 3.35 blue 
line). 
 
Figure 3.35.  Size-exclusion chromatography of Cx32 solubilized in 0.5% SDS (red) and then refolded in 
amphipol A8-35 (blue) by SDS precipitation as its potassium salt. With yellow elution profile of Cx32 
transferred into DDM after amphipol refolding is shown. Cx32 in 0.5% SDS after purification by metal affinity 
chromatography was loaded onto pre-equilibrated with equilibration buffer (with the same SDS concentration) 
Superose6HR 24 ml column and eluted in the same buffer with 0.1 ml/min flow speed. For refolded in A8-35 
connexin 32 equilibration buffer without any detergent was used. For Cx32/DDM 0.2% DDM solution in the 
same buffer was used for column equilibration. With green elution profile of A8-35 is shown. Grey lines 
correspond to calibration with globular proteins. 
Since connexin was expressed in E.coli some lipids might be still associated with 
protein even after purification. This may explain observed peak widening in comparison to 
Cx32/A8-35 from CFPS. In CFPS most E.coli lipids are removed from lysate on preparation 
stage so much less of them appear in the expression mixture. Cx32/A8-35 peak shift in 
comparison with Cx32/SDS peak may indicate that in case of amphipol less detergent 
molecules are involved in hemichannel stabilization and that protein is less unfolded. For 
further in meso crystallization experiments it was important to remove excessive amphipol, 
not-associated with the hemichannel. With this size-exclusion chromatography also helped, 
since amphipol without protein migrated significantly faster (Figure 3.35 green line) and 
could be eliminated in such a manner from the protein sample. 
Since Cx26 solubilized in DDM [10] was successfully crystalized we decided to try 
replacing A8-35 with DDM. For this purpose to Cx32/A8-35 eluate after size-exclusion 
chromatography we added 1% DDM. The sample was incubated for 1 h at 4°C with gentle 
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stirring. Then it was applied onto Superose6HR 24 ml column pre-equilibrated with a buffer 
containing 0.2% DDM. Elusion profile is shown on Figure 3.35 with yellow line. Significant 
peak widening indicates that Cx32 is destabilized when transferred to DDM and may be also 
partially unfolded. For this reason we decided to decline this procedure. For further 
crystallization Cx32/A8-35 complex was chosen. 
 
3.3.1.2. DLS with Cx32 in amphipol 
To study refolded into amphipol connexin monodispersity dynamic light scattering 
was used. The middle of the Cx32/A8-35 peak after size-exclusion chromatography was 
analyzed. Results are shown on Figure 3.36. 
 
Figure 3.36. DLS measurements of Cx32/A8-35 
complex monodispersity. The middle of Cx32/A8-35 
peak after size-exclusion chromatography was 
analyzed. Measurements were carried out at 20 °C. 
Main fraction of particles in the sample had hydrodynamic radius of 5.8 nm that is in a 
good agreement with the previously reported data for Cx26 hemichannel [190]. The 
deviations of 0.4 nm can be explained by method error and lipids depletion during 
purification process. 
 
3.3.1.3. Electron microscopy with Cx32 in amphipol and DDM 
For electron microscopy analysis fractions with connexin 32 refolded in amphipol 
after size-exclusion chromatography corresponding to hexamer (200 kDa) by size were 
supplied. Resulting photographs are shown on Figure 3.37 (A and B). Observed particles had 
the size that was in a good agreement with the previously reported for connexin 32 solubilized 
from gap junctional plaques [16]. The size distribution and presence of small aggregates were 
caused by amphipol, since the same effects were previously reported in case of 
bacteriorhodopsin trapped with amphipol [191]. Absence of doughnut-shaped connexons 
could be explained by pore blockage with side-chain groups of amphipol or with C-terminus 
of connexin 32 (also polyhistidine tag might make a contribution).  
0 
20 
40 
60 
80 
100 
5,8 1471,2 10019,7 215752 
%
 In
te
ns
ity
 
R, nm %	  Intensity	  
 84 
 
Figure 3.37. Solubilized connexin 32 negatively stained with uranyl acetate. (A) and (B) Cx32 was solubilized 
from total E.coli membranes in 1% NLS, purified by affinity chromatography in 0.2% SDS and then refolded in 
amphipol A8-35 by SDS precipitation as its potassium salt. Prior to EM analysis Cx32 was additionally purified 
by size-exclusion chromatography, excessive amounts of amphipol not associated with connexin were removed. 
(C) and (D) Cx32 transferred to DDM after amphipol assisted refolding from SDS. Before EM measurements 
the sample was applied to Superose6HR 24 ml column, pre-equilibrated with 0.2% DDM to remove amphipol. 
Fractions corresponding to dodecamer by size were further studied by EM. (A), (B) and (C) bars 20 nm, (D) bar 
– 100 nm. 
Transfer of Cx32 from amphipol to DDM resulted in protein aggregation (C and D) 
that corresponded to observed SEC peak widening (Figure 3.35 yellow line). Connexons 
were probably destabilized with A8-35 removal, which resulted in their aggregation. 
 
3.3.1.4. Crystallization of Cx32/amphipol in meso 
Fractions corresponding by size to hemichannel after size-exclusion chromatography 
of Cx32 refolded into amphipol were concentrated to final protein concentration 30 mg/ml 
using centrifugal filter with membrane cut-off 30 kDa. Protein concentration was controlled 
by NanoDrop spectrophotometer. 
Detergents (OG, DDM, FOS12) were added to the concentrated protein solution till the 
aimed concentration is achieved (12% OG, 24-30% DDM, 30% Fos12). Detergent 
A                                                                B 
C                                                                D 
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concentration was checked by IR spectroscopy. The protein solution was added to 
monooleoyl in a ratio 1:1 (vol:vol) and several passes through interconnected syringes for 
cubic phase preparation were performed. Cubic phase was incubated overnight at room 
temperature and then used for crystallization screenings. 
Crystallization was carried out using robot “NT 8 Crystallography” for in meso 
membrane protein crystallization. Crystallization probes were visualized and systematically 
scanned by automated system for imaging crystallization probes. 
Till now (two months) no crystals have been observed in the probes. But since in case of 
bacteriorhodopsin under certain crystallization conditions first crystals were found only after 
6 months we continue crystallization experiments with Cx32/A8-35 varying different 
parameters.  
 
3.3.2. Purification in NLS/DDM 
To obtain Cx32 solubilized in “mild” DDM or Fos12 first we tried to replace NLS on 
Ni2+-NTA column. For this the same procedure as described above was used only SDS in all 
buffers was replaced with either 0.2% DMM or 0.2% Fos12. Unfortunately, no connexin 32 
was observed in the eluates, seemed that it stuck on the resin. 
Then we decided to try “two-detergent” approach, previously used for purification of 
Cx32 in fusion to Mistic. Isolation and washing of E.coli total membranes was done 
following the same procedure as described above. On solubilization stage combination of two 
detergents was added – either 1% NLS and 1% DDM or 1% NLS and 1% Fos12. First, more 
“mild” detergent was added to the membranes suspension and the mixture was incubated for 1 
h at 4°C with vigorous mixing. Next, NLS was added and solubilization was carried out 
overnight. 
The supernatants after removal of insoluble fragments by centrifugation were diluted 
with solubilization buffer to reduce NLS concentration to 0.5%, 20 mM Imidazole was added 
to increase binding specificity. The mixtures were applied to Ni2+-NTA columns pre-
equilibrated with solubilization buffer (containing 0.5% NLS/0.5% DDM or 0.5% NLS/0.5% 
Fos12). Columns were washed with 5×CV of washing buffer with 0.5% of both detergents. 
Then, washing with 5×CV of washing buffer, containing only “mild” detergents (0.2% DDM 
or 0.2% Fos12) was carried out. Finally, bound proteins were eluted in 2×CV of elution 
buffer containing same concentrations of “mild” detergents. The purifications on 
chromatographic system were done at 4°C. 
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To study oligomeric composition of purified connexin 32 these eluates were further 
subjected to size-exclusion chromatography. The detergent concentrations in the elution 
buffer corresponded to the ones of Ni2+-NTA elution buffers. Resulting chromatograms are 
illustrated on Figure 3.38. 
 
Figure 3.38. Size-exclusion chromatography of Cx32 solubilized in 0.2% Fos12 (blue) or 0.2% DMM (red). 
Cx32 in 0.2% Fos12 or 0.2% DDM after purification by metal affinity chromatography was loaded onto pre-
equilibrated with equilibration buffers (with the same Fos12 and DDM concentrations) Superose6HR 24 ml 
column and eluted in the same buffers with 0.1 ml/min flow speed. Grey lines correspond to calibration with 
globular proteins. With green elution profile of Cx32 refolded in amphipol after SDS precipitation is depicted. 
In Fos12 (blue line) several oligomeric states were present, which indicated that it did 
not stabilize desirable hexamers properly and could not be used for its purification. In DDM 
we also observed polydispersity (red line). But particles with 200 kDa size dominated and 
could be separated from others. This allows preparing monodisperse sample, suitable for 
further crystallization by vapor diffusion method. 
 
3.3.2.1. EM with Cx32 purified in DDM 
Again for electron microscopy analysis fractions with connexin 32 solubilized and 
purified in DDM and Fos12 after SEC corresponding to hexamer (200 kDa) by size were 
supplied. Resulting photographs are shown on Figure 3.39.  
In case of DDM usage for solubilization and purification (Figure 3.39A) observed 
particles had similar geometry and size distribution as previously received for Cx32 refolded 
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in amphipol (Figure 3.37A). This time we also did not observe doughnut-shaped connexons 
and again blamed detergent and C-terminus. 
 
Figure 3.39. Solubilized connexin 32 negatively stained with uranyl acetate. (A) Cx32 was solubilized from 
total E.coli membranes in 1% NLS and 1% DDM, purified by affinity chromatography in 0.2% DDM. Prior to 
EM analysis Cx32 was additionally purified by size-exclusion chromatography, the peak corresponding by size 
to hexamer was further supplied for EM. (B) Cx32 was solubilized from total E.coli membranes in 1% NLS and 
1% Fos12, purified by affinity chromatography in 0.2% Fos12. As for DDM the peak corresponding by size to 
hexamer after size-exclusion chromatography was further supplied for EM. Bars, 20 nm. 
Again for electron microscopy analysis fractions with connexin 32 solubilized and 
purified in DDM and Fos12 after SEC corresponding to hexamer (200 kDa) by size were 
supplied. Resulting photographs are shown on Figure 3.39.  
In case of DDM usage for solubilization and purification (Figure 3.39A) observed 
particles had similar geometry and size distribution as previously received for Cx32 refolded 
in amphipol (Figure 3.37A). This time we also did not observe doughnut-shaped connexons 
and again blamed detergent and C-terminus. 
In case of Fos12 observed by SEC sample inhomogeneity was visualized also by EM. 
Some filament-like aggregates were found in the sample. Similar particles were previously 
reported when purified Cx32 was incubated with polyethylene glycol 2000 [16]. 
  
A                                                                B 
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Appendix 
Genes of proteins used in this work for generating Cx32 constructs are listed below. 
Mistic (MstX) from Bacillus subtilis: 
atgttttgtacattttttgaaaaacatcaccggaagtgggacatactgttagaaaaaagcacgggtgtgatggaagctatgaaagtgac
gagtgaggaaaaggaacagctgagcacagcaatcgaccgaatgaatgaaggactggacgcgtttatccagctgtataatgaatcg
gaaattgatgaaccgcttattcagcttgatgatgatacagccgagttaatgaagcaggcccgagatatgtacggccaggaaaagcta
aatgagaaattaaatacaattattaaacagattttatccatctcagtatctgaagaaggagaaaaagaa 
 
Wild type human connexin 32: 
atgaactggacaggtttgtacaccttgctcagtggcgtgaaccggcattctactgccattggccgagtatggctctcggtcatcttcatctt
cagaatcatggtgctggtggtggctgcagagagtgtgtggggtgatgagaaatcttccttcatctgcaacacactccagcctggctgca
acagcgtttgctatgaccaattcttccccatctcccatgtgcggctgtggtccctgcagctcatcctagtttccaccccagctctcctcgtgg
ccatgcacgtggctcaccagcaacacatagagaagaaaatgctacggcttgagggccatggggaccccctacacctggaggaggt
gaagaggcacaaggtccacatctcagggacactgtggtggacctatgtcatcagcgtggtgttccggctgttgtttgaggccgtcttcat
gtatgtcttttatctgctctaccctggctatgccatggtgcggctggtcaagtgcgacgtctacccctgccccaacacagtggactgcttcg
tgtcccgccccaccgagaaaaccgtcttcaccgtcttcatgctagctgcctctggcatctgcatcatcctcaatgtggccgaggtggtgt
acctcatcatccgggcctgtgcccgccgagcccagcgccgctccaatccaccttcccgcaagggctcgggcttcggccaccgcctct
cacctgaatacaagcagaatgagatcaacaagctgctgagtgagcaggatggctccctgaaagacatactgcgccgcagccctgg
caccggggctgggctggctgaaaagagcgaccgctgctcggcctgc 
 
Optimized gene of human connexin 32: 
atgaattggaccggtctgtataccctgctgagcggtgttaatcgtcatagcaccgcaattggtcgtgtttggctgagcgtgatttttatctttc
gtattatggttctggttgtggcagcagaaagcgtttggggtgatgaaaaaagcagctttatttgcaataccctgcagcctggttgtaatag
cgtttgttatgatcagttttttccgattagccatgttcgtctgtggtcactgcagctgattctggttagcacaccggcactgctggttgcaatgc
atgttgcacatcagcagcatatcgagaaaaaaatgctgcgtctggaaggtcatggtgatccgctgcacctggaagaagttaaacgtc
ataaagttcatattagcggcaccctgtggtggacctatgttattagcgttgtttttcgtctgctgtttgaagccgttttcatgtatgttttctatctg
ctgtatccgggttatgcaatggttcgtctggttaaatgtgatgtttatccgtgtccgaataccgttgattgttttgttagccgtccgaccgaaa
aaaccgtttttaccgtgtttatgctggcagcaagcggtatttgtattattctgaatgttgccgaagtggtgtatctgattattcgtgcatgtgca
cgtcgtgcccagcgtcgtagcaatccgcctagccgtaaaggtagcggttttggtcatcgtctgagtccggaatataaacagaacgaaa
ttaacaaactgctgtccgaacaggatggtagcctgaaagatattctgcgtcgtagtccgggtacaggtgcaggtctggcagaaaaaa
gcgatcgttgtagcgcatgt 
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Abstract 
 
The genome sequencing projects reveal that integral membrane proteins represent up to 
one third of the predicted proteins of all organisms examined so far. Furthermore, membrane 
proteins are targets of the large majority of the drugs that are currently in use. About 80% of 
all cellular responses are thought to occur through the proteins linked to the cell membrane. 
An ultimate understanding of their function depends on detailed structural data for each class 
of membrane proteins, such as transporters, receptors, channels and pumps. The structural 
information could also greatly improve the efficiency of drug discover. To date, the 3D 
structures of only a tiny fraction of membrane proteins (around 218) are known in atomic 
details, though structures of around 50000 soluble proteins have already been solved. 
Difficulties to determine 3D structures of integral membrane proteins are related to their 
low natural abundance, hydrophobic nature, and inhomogeneity due to post-translational 
modifications. They are expressed at rather low levels and usually constitute less than 30% of 
a total cellular protein. This requires developing of an efficient overexpression system to 
produce a sufficient amount of protein for crystallization experiments. 
E.coli is a convenient host for heterologous protein expression. Its advantages include 
well-established protocols, fast growth, high level of expression and scalability of 
experiments and low cost. Also it is important to mention that 80% of all protein structures 
deposited in the protein data bank were overexpressed in E.coli. However, heterologous gene 
expression in E.coli can lead to the production of misfolded, aggregated, and/or nonfunctional 
target proteins. This is often due to the absence of cofactors or lack of post-translational 
modifications required for function, stability and folding. 
Taken together these features make the development of methods for the study of 
membrane proteins lag far behind those of soluble proteins. Finally, one has to point out that 
large amounts of pure and homogeneous protein are absolute prerequisites to begin with 
crystallization experiments.  
Connexins are the class of membrane proteins. In living organisms connexins are the 
principal protein component of gap junctions – specialized cell-cell junctions that directly link 
the cytoplasm of adjacent cells. Recent discoveries provide the direct evidence that gap 
junctional intercellular communication is essential for tissue functions and organs 
development, and that its dysfunction causes diseases. At least nine human maladies are 
currently associated with mutations in genes encoding connexins. Also there are strong 
evidences that connexins function as malignant tumor suppressors. 
Despite connexins relevance and the fact that connexin studies have been started long 
time ago atomic resolution structure of gap junction formed by human connexin 26 is only 
available. This is mostly explained by high complexity of overexpression and purification of 
connexins in sufficient for crystallization amounts in mammalian or insect cells, which are 
commonly used for functional expression of mammalian proteins. The second problem is that 
connexins are subjected to post-translational modifications, which need to be removed to 
proceed with crystallization. And each additional purification step is crucial for final protein 
yield. On the other hand expression of recombinant proteins in E.coli eliminates most of post-
translational modifications and can solve the problem.  
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Human connexin 32 among other members of connexin family it is one of the best 
studied. A lot of data concerning its conductance and permeability properties are available. 
Furthermore, connexin 32 was previously successfully produced and purified from 
mammalian cells, in vitro, and from baculovirus/insect cells. That is why there exists a good 
possibility to compare functional properties of this connexin overexpressed in different 
systems. However, previous attempts at expression and purification of full-length connexin 32 
from E.coli were not successful. In this work, we show that this is indeed possible. We 
developed the protocol for expression and purification of functional protein, able to form 
hemichannels. It is important to stress that there is no experimental atomic resolution structure 
of connexin 32 that can elucidate its mechanism of function. Understanding the great demand 
for atomic structure two models based on cryo-electron microscopy maps were proposed. But 
still high-resolution X-Ray structure of connexin 32 is to be determined.  
To summarize, in this work we overexpressed connexin 32 using membrane-targeting 
expression tag. Membrane-integrating protein MstX from Bacillus subtilis was attached to N-
terminus of Cx32 and helped to increase tremendously expression yield. Since addition of N-
terminal extensions suppresses connexins functions all excessive amino acids must be 
removed. We demonstrated that MstX is resistant to various cleavage conditions including 
different proteases usage and variations of linker in between. Also we expressed Cx32 
without any expression tag in vitro using E.coli S30 extract and refolded purified connexins 
into hemichannels. Then, since expression yield was still not high enough, we did broad 
screening of cell free reaction conditions and examined influence of short peptides addition 
on N-terminus. Next, we managed to express and purify connexin 32 from E.coli using 
certain gene sequence optimization. The refolding procedure was developed and Cx32 
functionality was confirmed by assembling it into hemichannels. Further this protein was used 
for crystallization experiments. 
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Zusammenfassung 
 
Genomsequenzierungsprojekte zeigen, dass integrale Membranproteine bei allen bisher 
untersuchten Organismen bis zu ein Drittel der vorhergesagten Proteine ausmachen. Darüber 
hinaus zielt die große Mehrzahl heute verwendeter medizinischer Wirkstoffe auf 
Membranproteine ab. Es wird angenommen, dass etwa 80 % aller Zellreaktionen über die mit 
der Zellmembran verbundenen Proteine ablaufen. Ein abschließendes Verständnis ihrer 
Funktion erfordert detaillierte Strukturdaten für alle Arten von Membranproteinen, z. B. 
Transporter, Rezeptoren, Kanäle und Pumpen. Diese Strukturinformationen könnten auch die 
Effizienz bei der Entdeckung neuer Wirkstoffe stark erhöhen. Obwohl die Struktur von etwa 
50.000 löslichen Proteinen bereits aufgeklärt werden konnten, ist bis heute nur von einem 
kleinen Bruchteil der Membranproteine (ca. 218) die 3-D-Struktur auf atomarer Ebene 
bekannt. 
Schwierigkeiten bei der Bestimmung der 3-D-Strukturen integraler Membranproteine 
hängen mit ihrem geringen natürlichen Vorkommen, ihrer hydrophoben Beschaffenheit und 
der Inhomogenität aufgrund posttranslationaler Modifikationen zusammen. Sie werden in 
recht kleinen Mengen exprimiert und machen in der Regel weniger als 30 % des 
Gesamtvorkommens eines Zellproteins aus. Es muss daher ein effizientes System für die 
Überexpression entwickelt werden, um eine für die Kristallisation ausreichende Proteinmenge 
herzustellen. 
E. coli ist ein geeigneter Wirt für die heterologe Proteinexpression. Seine Vorteile liegen 
in den gut etablierten Protokollen, seinem schnellem Wachstum, der hohen 
Expressionsausbeute und der Skalierbarkeit von Versuchen sowie den niedrigen Kosten. 
Darüber hinaus wurden 80 % aller in der Proteindatenbank hinterlegten Proteinstrukturen in 
E. coli überexprimiert. Die heterologe Genexpression in E. coli kann jedoch zu fehlgefalteten, 
aggregierten und/oder nicht funtionellen Zielproteinen führen. Dies ist häufig auf die 
Abwesenheit von Kofaktoren oder einen Mangel an posttranslationalen Modifikationen 
zurückzuführen, die für Funktion, Stabilität und Faltung erforderlich sind. 
Aufgrund all dieser Faktoren liegt die Methodenentwicklung für die Untersuchung von 
Membranproteinen im Vergleich zu löslichen Proteinen noch weit zurück. Nicht zuletzt sind 
große Mengen reinen, homogenen Proteins eine Grundvoraussetzung für 
Kristallisationsversuche.  
Connexine sind eine Familie von Membranproteinen. In lebenden Organismen sind 
Connexine die wichtigste Komponente von 'Gap Junctions' – speziellen Kontaktstellen 
zwischen Zellen, die das Cytoplasma benachbarter Zellen direkt miteinander verbinden. Neue 
Untersuchungen haben den direkten Nachweis dafür erbracht, dass die interzelluläre 
Kommunikation zwischen Zellen über Gap Junctions für die Gewebefunktion und 
Organentwicklung unverzichtbar ist und dass Fehlfunktionen Krankheiten auslösen. 
Mindestens neun menschliche Erkrankungen werden derzeit mit Mutationen in 
Connexingenen in Verbindung gebracht. Darüber hinaus gibt es starke Hinweise darauf, dass 
Connexine das Wachstum bösartiger Tumore hemmen.  
Trotz der Bedeutung von Connexinen und der Tatsache, dass sie bereits seit einiger Zeit 
untersucht werden, ist bisher nur für das menschliche Connexin 26 die atomare Struktur der 
Gap Junction bekannt. Dies ist vor allem auf die hohe Komplexität der Überexpression und 
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Aufreinigung von Connexinen in für die Kristallisation ausreichenden Mengen bei Säugetier- 
bzw. Insektenzellen zurückzuführen, die häufig für die funktionelle Expression von 
Säugetierproteinen verwendet werden. Eine weitere Schwierigkeit liegt in der Tatsache, dass 
in Connexinen posttranslationale Modifikationen stattfinden, die vor der Kristallisation 
entfernt werden müssen. Dabei entscheidet jeder einzelne Aufreinigungsschritt über die 
schließlich erzielte Proteinausbeute. Andererseits werden durch die Expression rekombinanter 
Proteine in E. coli die meisten posttranslationalen Modifikationen eliminiert, so dass sie zur 
Lösung des Problems beitragen kann.  
Menschliches Connexin 32 gehört zu den am besten untersuchten Vertretern der 
Connexinfamilie. Es liegt eine große Menge an Daten zu seinen Leitfähigkeits- und 
Permeabilitätseigenschaften vor. Darüber hinaus wurde Connexin 32 bereits erfolgreich aus 
Säugetierzellen, in vitro und aus Bakuloviren-/Insektenzellen hergestellt und aufgereinigt. Die 
Chancen stehen daher gut, dass die funktionellen Eigenschaften dieses Connexins bei 
Überexpression in verschiedenen Systemen verglichen werden können. Versuche der 
Expression und Aufreinigung des vollständigen Connexins 32 aus E. coli waren jedoch bisher 
nicht erfolgreich. In dieser Arbeit wird jedoch gezeigt, dass dies tatsächlich möglich ist. Es 
wurde ein Protokoll für die Expression und Aufreinigung von funtionellen Proteinen 
entwickelt, die Hemikanäle bilden können. Dabei ist hervorzuheben, dass aus Versuchen 
keine atomar auflösende Struktur von Connexin vorliegt, die seinen Funktionsmechanismus 
erklären könnte. Aufgrund der großen Bedeutung der atomaren Struktur wurden basierend auf 
kryoelektronenmikroskopischer Bilder zwei Modelle vorgeschlagen. Eine hochauflösende 
Röntgenstrukturanalyse von Connexin 32 steht jedoch noch immer aus.  
In dieser Arbeit wurde Connexin 32 mithilfe eines Membranexpressions-Tags 
überexprimiert. Das integrale Membranprotein MstX aus Bacillus subtilis wurde am N-
Terminus von Cx32 angebaut, was zu einer enormen Verbesserung der Expressionsausbeute 
beitrug. Da die Zugabe N-terminaler Erweiterungen Connexinfunktionen unterdrückt, müssen 
alle überschüssigen Aminosäuren entfernt werden. Es konnte gezeigt werden, dass MstX 
gegenüber verschiedenen Spaltungsbedingungen resistent ist, darunter der Verwendung 
verschiedener Proteasen und der Variation des zwischengeschalteten Linkers. Außerdem 
wurde Cx32 ohne Expressions-Tag unter Verwendung von S30-Extrakt von E. coli in vitro 
exprimiert und die aufgereinigten Connexine wurden wieder in Hemikanäle gefaltet. Da die 
Expressionsausbeute noch immer nicht ausreichend war, wurde ein grobes Screening der 
Bedingungen für zellfreie Reaktionsvorgänge durchgeführt und der Einfluss einer Zugabe 
kurzer Peptide am N-Terminus untersucht. Daraufhin konnte Connexin 32 durch Optimierung 
einer bestimmten Gensequenz in E. coli exprimiert und aufgereinigt werden. Es wurde ein 
Vorgehen für die Neufaltung entwickelt und die Funktionalität von Cx32 wurde durch die 
Neufaltung des Proteins in Hemikanäle nachgewiesen. Das Protein wurde darüber hinaus 
auch für Kristallisationsversuche verwendet. 
 
 
